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ABSTRACT
BACKGROUND: Arthritis is increasingly becoming a public health concern as it is the leading
cause of disability. Glucosamine and chondroitin, which are alternative dietary supplements, are
commonly marketed for persons with joint pain. The purpose of this study is to examine if selfreported 12-month and past 30-day use of glucosamine and/or chondroitin among persons with
any arthritis, unspecified arthritis, and rheumatoid arthritis is associated with reports of past 12
month improved health and reports of past 30-day joint pain, aching, and stiffness, respectively.
METHODS: The 2012 National Health Interview Survey (NHIS), a nationally representative
cross-sectional household interview survey, was used for this study. The adult sample consisted
of 34,525. Subgroup analyses were conducted on 7,654 respondents with any arthritis, 6,016
with unspecified arthritis, and 898 with rheumatoid arthritis. The independent variables were
defined as the use of glucosamine only, chondroitin only, or glucosamine and chondroitin one or
more times in the past 12 months and past 30 days. The dependent variables were defined as selfreported past 12 month improved health and past 30 day pain, aching, and stiffness. Descriptive,
bivariate, and multivariate analyses were conducted using SAS 9.4 accounting for the complex
survey design, computing missing values as missing completely at random for variance
estimation. All multivariate logistic regression models included sociodemographics, use of other
alternative therapies, and any other chronic conditions.
RESULTS: Approximately 21.8% of U.S adults had any arthritis, 17.0% had unspecified
arthritis and 2.5% had rheumatoid arthritis. Among persons with any arthritis, approximately
3.7% used glucosamine, 0.4% used chondroitin, and 3.4% used both glucosamine and
chondroitin within the past 12 months while approximately 5.1% used glucosamine, 0.6% used
chondroitin, and 0.4% used both glucosamine and chondroitin within the past 30 days. Among
persons with unspecified arthritis, approximately 3.7% used glucosamine, 0.5% used
chondroitin, and 3.8% used both glucosamine and chondroitin within the past 12 months while
5.5% used glucosamine, 0.5% used chondroitin, and 0.4% used both glucosamine and
chondroitin within the past 30 days. Among persons with rheumatoid arthritis, approximately
2.4% used glucosamine, 0.3% used chondroitin, and 2.1% used both glucosamine and
chondroitin within the past 12 months while approximately 2.9% used glucosamine, 0.7% used
chondroitin, and 0.5% used both glucosamine and chondroitin within the past 30 days. Women
used more of all supplements (past 12 months and past 30 days) except past 12 month use of
chondroitin among persons with any arthritis. Persons 56 to 70 years old had the highest
proportion of past 12 month and 30 day supplement use among persons with unspecified
arthritis.
After adjusting for sex, age, race, BMI, poverty level, other health conditions, and other CAM
therapies (acupuncture, energy, mind-body, and chiropractic/osteopathic therapies), the use of
chondroitin only (adjusted OR= 0.6; p= <0.01) and the use of both glucosamine and chondroitin
(adjusted OR= 5.7; p= <0.01) during the past 30 days was associated with self-reported past 30
day joint pain, aching, and stiffness among persons with any arthritis. After adjusting for age,
BMI, poverty level, region, other health conditions, and other CAM therapies (acupuncture,
energy, mind-body, and chiropractic/osteopathic therapies), the use of chondroitin only was also
associated with past 30 day joint pain, aching, and stiffness among persons with unspecified
arthritis (adjusted OR= 0.5; p= 0.02).

CONCLUSION: Chondroitin alone was associated reports of past 30 day joint pain, aching, and
stiffness among persons with any arthritis and unspecified arthritis highlighting a potential
effective role and use for this supplement. In addition, the use of both glucosamine and
chondroitin were associated with reports of past 30 day joint pain, aching, and stiffness among
persons with any arthritis. Marketing may play a role in these relationships and should be further
examined.
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CHAPTER I
INTRODUCTION
BACKGROUND
Arthritis is the inflammation of one or more joints, and includes several rheumatic
diseases and conditions. Arthritis is a disease that naturally worsens with age. Because the
workforce in the United States is aging, arthritis is increasingly becoming a public health issue.
In 2003, an estimated $128 billion in medical-care costs and lost earnings were due to arthritis
alone in the United States (CDC 2007). This estimate has only increased over the years.
Osteoarthritis and rheumatoid arthritis are the two most common forms of arthritis.
Osteoarthritis is characterized by progressive degeneration of articular cartilage (Gibson et al.
2014). Rheumatoid arthritis is a chronic inflammatory disease that results in damage to bone and
cartilage (Md Yusof & Emery 2013). Current treatment for these conditions mostly consists of
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Unfortunately, long-term use of
these treatments could potentially cause serious adverse gastrointestinal and cardiovascular
events (Wu et al. 2013). Using complementary and alternative medicine (CAM) therapies instead
of, or in combination with, these treatments can potentially decrease susceptibility to
experiencing these common side effects.
Complementary and alternative medicine (CAM) therapies are non-traditional medical
practices performed with the intent to treat or prevent a condition. There are various forms of
CAM therapies, which may include homeopathy, naturopathy, meditation and prayer, herbal and
dietary supplements, chiropractic and massage therapy, and energy therapies (NCCIH 2000).
Among adults with arthritis, the use of dietary supplements is one form of CAM that is becoming
widely used. Glucosamine and chondroitin are two supplements of interest. Glucosamine and
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chondroitin can be found separately or in combination pills. Both supplements are thought to
have a role in protecting joints from degeneration (Gibson et al. 2014; Stuber et al. 2011). The
classification of glucosamine and chondroitin as dietary supplements instead of pharmaceutical
drugs mean that they are not approved by the U.S Food and Drug Administration (FDA) for
medicinal use. However, the two supplements are typically safe to use (Barnes et al. 2008;
Dahmer & Schiller 2008). Currently, glucosamine and chondroitin, alone or in combination, are
marketed towards persons with arthritis. Glucosamine is also often used as a preventive measure
to maintain health, and has been identified as a potential treatment for pain relief of degenerative
disc disease (Hopman et al. 2006; Stuber et al. 2011). Glucosamine and chondroitin are of
particular interest because they could potentially be an effective way to reduce pain and restore
joint function in persons with arthritis while decreasing risk of adverse side effects.
While glucosamine and chondroitin appears to show some promise in reducing pain and
restoring joint function in persons with arthritis, findings from multiple studies have been
inconclusive about their true effectiveness in these functions. While some studies are finding
glucosamine and chondroitin to be moderately effective in decreasing pain and stopping the
progression of osteoarthritis (Bruyere & Reginster 2007; McAlindon et al. 2000), others are
finding the supplements to be no more effective than placebos (Clegg et al. 2006; Kwoh et al.
2014). What is also less understood is the proportion of adults with arthritis who use
glucosamine and/or chondroitin and derive any benefits from its use such as positive quality of
life or improved health and decreased pain. This study will contribute to this gap.
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RESEARCH QUESTIONS AND HYPOTHESES
1. What are the socio-demographic characteristics of U.S. adults with any arthritis, unspecified
arthritis and rheumatoid arthritis?
2. What are the socio-demographic characteristics of U.S. adults with any arthritis, unspecified
arthritis, and rheumatoid arthritis who use glucosamine and/or chondroitin?
3. Does self-reported improved health or joint pain, aching, and stiffness among U.S. adults with
any arthritis, unspecified arthritis, and rheumatoid arthritis differ based on glucosamine and/or
chondroitin use?


H10: Adults with any arthritis who report using glucosamine and/or chondroitin will not
differ from adults who do not use glucosamine and /or chondroitin on self-reported health
improvement in the past 12 months.



H20: Adults with unspecified arthritis who report using glucosamine and /or chondroitin
will not differ from adults who do not use glucosamine and /or chondroitin on selfreported health improvement in the past 12 months.



H30: Adults with rheumatoid arthritis who report using glucosamine and /or chondroitin
will not differ from adults who do not use glucosamine and /or chondroitin on selfreported health improvement in the past 12 months.



H40: Adults with any arthritis who report current glucosamine and/or chondroitin use will
not differ from adults who do not use glucosamine and /or chondroitin on self-reported
symptoms of joint pain, aching, and stiffness in the past 30 days.
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H50: Adults with unspecified arthritis who report current glucosamine and /or chondroitin
use will not differ from adults who do not use glucosamine and /or chondroitin on selfreported symptoms of joint pain, aching, and stiffness in the past 30 days.



H60: Adults with rheumatoid arthritis who report current glucosamine and /or chondroitin
use will not differ from adults who do not use glucosamine and /or chondroitin on selfreported symptoms of joint pain, aching, and stiffness in the past 30 days.
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CHAPTER II
REVIEW OF LITERATURE
OVERVIEW OF ARTHRITIS
Arthritis is the inflammation of one or more of joints, with osteoarthritis and rheumatoid
arthritis as the most common forms of arthritis (CDC 2014). Arthritic symptoms include pain,
aching, and swelling around the joints. Arthritis is the leading cause of disability and among the
leading causes of work limitations in adults (Helmick et al. 2008).
Though anyone can be affected, arthritis tends to be an illness of the aging population and
is most common among adults aged 65 years or older (CDC 2014). While the prevalence of
juvenile arthritis is often difficult to estimate due to differences in nomenclature and a consistent
case definition, NHIS data suggests a prevalence of 150 per 100,000 for all types of childhood
arthritis (Helmick et al. 2008). In addition to age, sex and weight are risk factors for arthritis
(CDC 2014).
In 2003, an estimated $128 billion in medical-care costs and lost earnings were due to
arthritis alone in the United States (CDC 2007). Analyzed data from the National Health
Interview Survey (NHIS) for years 2010-2012 found that 52.5 million (22.7%) of adults ages 18
years or older self-reported doctor-diagnosed arthritis. Of these people, 22.7 million reported
being limited in physical activity due to having arthritis. In addition, the prevalence of arthritis in
this population is greater among persons with other health complications when compared to the
general population prevalence of 22.7%. For example, the prevalence of doctor-diagnosed
arthritis among obese adults, persons with diabetes, and persons with heart disease was 31.2%,
47.3%, and 49.0% respectively (Barbour et al. 2013). Equally alarming is the prevalence of
persons with these conditions being limited in activity due to arthritis; the prevalence is 26.8%,
5

25.7%, and 15.2%, respectively. With arthritis driving cost and physically limiting the work
force, it is increasingly becoming a public health concern.
OSTEOARTHRITIS
Osteoarthritis is the most common form of arthritis and is characterized by progressive
degeneration of articular cartilage (Gibson et al. 2014). This disease is estimated to affect
approximately 15% of the population. The primary location of osteoarthritis is commonly seen in
the knee and hip, which is the leading cause of lower extremity disability amongst older adults
(Johnson & Hunter 2014). While the etiology of osteoarthritis is not fully understood, disease
progression can be divided into two phases at the cellular level: a biosynthetic phase and a
degenerative phase (Gibson et al. 2014). Chondrocytes are the mature cells found in cartilage.
These cells are partly responsible for maintaining the extracellular matrix (Mollenhauer 2008).
The biosynthesis phase begins when the extracellular matrix is damaged and the chondrocytes
fails to repair it. When this occurs, production of the extracellular matrix is inhibited causing
chondrocytes to release proteolytic enzymes, accelerating cartilage loss. This begins the
degenerative phase. By products of the extracellular matrix travel throughout the joint, creating
build up and inflammation that contributes to further disease progression (Hunziker 2002;
Mollenhauer 2008).
Because osteoarthritis is the result of the complex interaction between mechanical,
cellular, and biomechanical factors, there are several associated risk factors, which include: age,
gender, genetics, obesity, diet, and occupational and physical activity. Johnson and Hunter
identifies the increased risk of incident osteoarthritis through two categories: susceptible joints
and predisposed individual (Johnson & Hunter 2014). Susceptible joint is determined by five
modifiable risk factors: muscle strength, physical activity/occupation, joint injury, joint
6

alignment, and leg length inequality. Predisposed individuals, on the other hand, are determined
through two additional categories: modifiable systemic risk factors and non-modifiable systemic
risk factors. Modifiable systemic risk factors include: obesity, diet, and bone metabolism. Nonmodifiable systemic risk factors include: age, sex, genetics, and ethnicity.
Osteoarthritis can be ascertained using three different diagnostic approaches: pathological
screening, radiographical screening, or clinical screening (Johnson & Hunter 2014). Typically,
diagnosis is made using a radiographical or clinical screening. Clinically diagnosed osteoarthritis
is based on the examination revealing characteristic symptomology. Radiographical diagnosis of
osteoarthritis is based on graded radiographs according to the Kellgen and Lawrence (KL)
grading system. The KL grading system grades on a scale of 0 to 4. It assesses the severity of the
disease on a plain radiograph based on the visibility of joint space narrowing, osteocytes, and
bone deformity. Any grade greater than 2 results in a diagnosis of osteoarthritis (Johnson &
Hunter 2014). According to Elders, an estimated 60% of the United States’ population develops
radiographic evidence of osteoarthritis by the time they reach age 55 (Elders et al. 2000).
Radiographic knee and hip osteoarthritis each had a prevalence of 28% in the Johnston
County Osteoarthritis Project of African American and Caucasian men and women (Jordan et al.
2007; Jordan et al. 2009). These two studies also found reported prevalence rates of 17%
symptomatic knee osteoarthritis and 10% for symptomatic hip osteoarthritis. These prevalence
rates are different because all persons with radiographic osteoarthritis do not experience
concomitant symptoms (Johnson & Hunter 2014).
A Sweden population based study found a proportion of 26.6% of persons aged 45 years
and older with any doctor-diagnosed osteoarthritis. The proportion of women, 30.5%, was higher
than the proportion of men, 22.4%. About 27% of the prevalent cases had osteoarthritis in
7

multiple joints (Turkiewicz et al. 2014). Prevalence of radiographic knee osteoarthritis in the
United States is 52.4% in African Americans, 36.2% in Whites, and 37.6% in Mexican
Americans (Lawrence et al. 2008).The prevalence is significantly higher in African Americans
when compared to Whites and Mexican Americans.
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is a chronic inflammatory disease that results in damage to bone and
cartilage. It is a term that includes several rheumatic diseases and conditions such as rheumatoid
arthritis, lupus, osteoarthritis, fibromyalgia, and gout. Symptoms of this condition include
fatigue, pain, and other extra-articular manifestations (Md Yusof & Emery 2013). Rheumatoid
arthritis is a fairly common disease that occurs two to three times more frequently in women than
in men (Gabriel 2001; Smolen & Steiner 2003). While it can occur at any age, prevalence peaks
are most common in the 4th and 6th decade of life. The most commonly affected joints are those
of the hands, feet, and knees (Smolen & Steiner 2003). While obesity is associated with
increased risk of arthritis, being underweight due to weight loss is associated with accelerated
mortality in rheumatoid arthritis (Baker et al. 2015).
The cause of rheumatoid arthritis is unknown. It is thought to have a polygenic basis
although the genes involved in pathogenesis have yet to be identified (Smolen & Steiner 2003).
What is clear is that rheumatoid arthritis is initiated by CD4+ T cells. These cells amplify the
immune response by stimulating other mononuclear cells, synovial fibroblasts, chondrocytes,
and osteoclasts. Cytokines such as TNF-a, interleukin-1, and interleukin-6 are released resulting
in synovial inflammation (Choy & Panayi 2001). Long term inflammation results in the joint
damage that is associated with rheumatoid arthritis. Patients with arthritis have synovial
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membranes that are characterized by hyperplasia, increased vascularity, and an infiltrate of
inflammatory cells such as CD4+cells (Smolen & Steiner 2003).
About half of the patients newly diagnosed with rheumatoid arthritis are 65 years of age
and older (Waljee et al. 2015). A Quebec study found a prevalence of 9.9 per 1,000. This study
found a male prevalence of 4.1 per thousand and female prevalence of 5.6 per 1,000. In addition,
older women had a higher prevalence for any demographic group (Bernatsky et al 2014). A US
study analyzing data from Olmsted County, Minnesota from 1955 to 2006 found that the overall
annual age and sex adjusted rheumatoid arthritis incidence was about 40.9 per 100,000
(Myasoedova et al. 2010). Age adjusted incidence in women was much higher than in men.
Women had an age adjusted incidence of 53.1 per 100,000 while men had an age adjusted
incidence of 27.7 per 100,000. When extrapolated to the US population, 1.5 million US adults
were estimated to have arthritis in 2007 compared to 1.3 million reported in 1995 (Myasoedova
et al. 2010).
CURRENT TREATMENT
Pharmacological therapy for osteoarthritis and rheumatoid arthritis mostly consists of
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). This is particularly alarming
because the overuse of these drugs could cause serious adverse gastrointestinal and
cardiovascular events (Wu et al. 2013). In addition, analgesics and NSAIDs do not improve the
underlying structural cartilage damage. Patients with symptomatic hip or knee osteoarthritis that
use non-steroidal anti-inflammatory drugs are typically advised to use the lowest effective dose
and avoid long-term use if possible (Wu et al. 2013). In severe cases, joint replacement surgeries
may be deemed necessary.
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Disease-modifying anti-rheumatic drugs (DMARDs) are becoming more readily
available for rheumatoid arthritis (Smolen & Steiner 2003). Early therapy intervention can lead
to better disease control and lessen joint damage. Because treatment with disease-modifying
anti-rheumatic drugs (DMARDs) is only justified when the risk-benefit or cost-effectiveness
ratios are favorable, early detection is necessary for the use of these drugs (Visser et al. 2002).
Patients diagnosed at a later stage or who have had rheumatoid arthritis over a long period of
time, may have less pharmacological options and therefore may resort to complementary and
alternative medicine (CAM) therapies.
ALTERNATIVE THERAPIES FOR ARTHRITIS
Complementary and Alternative Medicine (CAM) therapies are treatment/prevention
strategies not considered to be a biomedical intervention. CAM therapies are becoming
increasingly difficult to define, as it includes a broad range of systems and strategies.
Throughout the literature, there is a lack of consistency of what should be considered CAM
therapies. This is partly due to scientific evidence that may or may not support these therapies
but, also due to political ramifications. Licensure is a sure form of recognition for any therapy
however, not all CAM therapies are licensed or many have few or no formal regulation.
Chiropractic, acupuncture, and massage therapy are licensed in most states while naturopathy
and homeopathy are licensed in fewer (Johnson & Hunter 2014).
While there are several CAM therapy classification systems, the most widely used
classification structure was developed by the National Center for Complementary and Integrative
Health (NCCIH), formerly known as the National Center for Complementary and Alternative
Medicine (NCCAM) (Kaptchuk & Eisenberg 2001; NCCIH 2000). According to this
classification system, there are five categories of CAM modalities: alternative medical systems,
10

mind-body interventions, biologically based treatments, manipulative and body-based methods,
and energy therapies (NCCIH 2000). Alternative medical systems refer to a paradigm or system
of theory that is not of conventional medicine. Homeopathy, Acupuncture, Ayurveda, and
naturopathy are example of alternative medical systems. Mind-body interventions are therapies
that are used to bring awareness to how stress, thoughts, and feelings can impact our physical
health. Mind-body interventions are typically those that help to reduce the “fight or flight”
response, which occurs during times of stress and which is used to calm the mind and assist in
emotional regulation. Meditation and prayer are just two examples of mind-body therapies, but
there are many others. Chiropractic and massage therapies are classified as manipulative and
body-based, which work towards aligning and reducing muscle tension, which often result from
physical or emotional stress and trauma. Energy therapies consist of the manipulation and
application of energy fields to the body. In the same way that electromagnetic fields exist outside
of the body, these therapies rely on the assumption that there too exist energy fields within the
body. Reiki and Qi Gong are examples of this classification type. Finally, biological based
therapies use herbal products, dietary supplements, hormones, and other natural products
(NCCIH 2000).
Several CAM therapies have been identified as being effective in symptom relief of
arthritic conditions such as acupuncture, energy, chiropractic/osteopathic, and mind-body
therapies, and dietary supplements- namely glucosamine and chondroitin. For example, a 2013
meta-analysis of physical treatments that included 114 trials, found acupuncture to be more
strongly associated with pain reduction than standard care among persons with osteoarthritis of
the knee (Corbett et al. 2013). A 2009 study of 40 patients with a mean age of 65 years found Tai
Chi to be effective in reducing pain and improving physical function and self-efficacy. It also

11

showed benefits for improving depression and health-related quality of life for knee osteoarthritis
(Wang et al. 2009). A systematic review on use of yoga for persons with arthritis found yoga to
be effective in improving self-efficacy and mental health, and in symptom reduction such as
tender/swollen joints, pain, and disability (Haaz & Bartlett 2011). In a clinical pilot trial, persons
with hip osteoarthritis waiting for arthroplasty, chiropractic therapy was proven to be effective in
improving self-rated hip pain, function in daily living, and hip related quality of life (Thorman et
al. 2010). In addition, a randomized clinical trial found that relaxation response training
significantly improves pain associated with rheumatoid arthritis (Barsky et al. 2010). This thesis
recognizes that there are other forms of CAM therapies that can influence reports of improved
health and joint pain, aching, and stiffness however, will focus on these outcome relationships
with glucosamine and/or chondroitin use. These other CAM therapies will be considered
potential covariates.
GLUCOSAMINE
Glucosamine is a naturally occurring amino-monosaccharide that is thought to be active
in protecting joints from degeneration (Gibson et al. 2014). It is an integral part of the normal
growth and repair of connective tissues (Henrotin et al. 2013). Glucosamine is a preferred
substrate for the production of aggrecans and other proteoglycans in cartilage (Wu et al. 2013).
As one of the major constituents of the extracellular matrix (ECM), its potential
chondroprotective properties are key. Glucosamine supplements can be found on the shelves of
pharmacies and many grocery stores and are commonly sold in two forms: glucosamine sulfate
and glucosamine hydrochloride. Of the two, glucosamine sulfate has been identified as the more
promising supplement in alleviating pain and symptoms associated with arthritis due to its
structure and function (Henrotin et al. 2013).
12

Glucosamine is currently classified as a dietary supplement and not a drug, therefore is
not approved by the U.S Food and Drug Administration (FDA) for medicinal use (Barnes et al.
2008). However, glucosamine is among the most commonly used CAM treatments among
persons with arthritis. For example, when current CAM use was observed in a study of 612
patients with arthritis, glucosamine use (about 34.1%) was reported the most (Herman et al.
2004). In addition to use for arthritic symptoms, glucosamine is also used as a preventive
measure to maintain health, and has been identified as a potential treatment for pain relief of
degenerative disc disease (Hopman et al. 2006; Stuber et al. 2011). Reported adverse effects of
glucosamine are generally uncommon and minor (Dahmer & Schiller 2008). However,
intravenous administration of glucosamine was shown to cause insulin resistance and endothelial
dysfunction in animal models. A 2006 study set out to determine if oral glucosamine is likely to
cause or worsen these conditions in lean or obese subjects (Muniyappa et al. 2006). Findings
from this study suggest that standard doses of oral glucosamine for six weeks does not cause or
worsen insulin resistance or endothelial dysfunction in lean or obese subjects.
CHONDROITIN
Chondroitin is often found in combination supplement pills with glucosamine. Because
chondroitin constitutes the majority of the glycosaminoglycans in articular cartilage, it is
speculated to be active in maintaining the viscosity in joints, stimulating cartilage repair, and
inhibiting enzymes responsible for cartilage degeneration (Stuber et al. 2011). For this reason, it
is mostly used among persons with arthritis to decrease pain and other associated symptoms
through its potential structural modifying effects. While chondroitin is considered a generally
safe supplement, similar to glucosamine, chondroitin is classified as a dietary supplement and
therefore, is not approved by FDA for medicinal purposes (Barnes et al. 2008).
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SOCIODEMOGRAPHICS OF GLUCOSAMINE/CHONDROITIN USE
A 2008 study analyzing 2007 National Health Interview Survey (NHIS) data found that
38% of adults 18 years and older in the Northeast region were CAM users while 41.4% were
users in the Midwest, 32.5% in the South, and 44% in the West. This same study shows that
persons age 50-59 years of age had the highest prevalence of CAM use (Barnes et al. 2008). In a
study observing CAM use among overweight and obese persons with radiographic knee
osteoarthritis, BMI was inversely associated with CAM use. Persons classified as obese (BMI
≥30 kg/m2) were less likely to use CAM therapies, alone or in combination with conventional
medications when compared to persons underweight or normal weight (BMI <25 kg/m2) (Lapane
et al. 2013). While there are studies on the distribution of general use of complementary and
alternative therapies (CAM), less is known about glucosamine and/or chondroitin use.
Understanding the socio-demographic characteristics of glucosamine and/or chondroitin use is
important for this thesis.
An Australian study of persons 45 years of age and older found that higher income is
associated with glucosamine use (Sibbritt et al. 2012). A Canadian study, similarly, found that
glucosamine use occurred more in the western regions when compared to all other regions
(Hopman et al. 2006). In addition, it is estimated that almost 400,000 elderly diabetic persons in
the U.S use glucosamine (Simon et al. 2011).
A 2006 study using the US Food and Administration 2002 Health and Diet Survey found
that glucosamine sulfate or glucosamine and chondroitin constituted 10.9% of the use of specific
herbs, botanicals, and other nonvitamin/nonmineral dietary supplements during the past 12
months (Timbo et al. 2006). Prevalence of persons using chondroitin 45 to 64 years of age was
2.3% while prevalence of its use for persons 65 years of age and older was 3.9% in 2002. The
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prevalence of chondroitin use in 2002 has increased since 1998/1999 (Kelly et al. 2005).
However, there has been 12 years since this study. This thesis will determine if changes in
chondroitin use has changed since 2002.

CLINICAL STUDIES

A systematic review conducted by Bruyere and Reginster, which included eight primary
trials over a 12 month period, found glucosamine sulfate and chondroitin to be effective in
showing improvements in joint space loss, pain, and function (Bruyere & Reginster 2007). The
same review, analyzing two additional studies, found glucosamine sulfate to reduce the need for
knee arthroplasty from 14.5% to 6.3% at eight years’ follow-up. This study concluded that there
is evidence that glucosamine sulfate and chondroitin sulfate may interfere with progression of
osteoarthritis with respect to the structure modifying effect (Bruyere & Reginster 2007).
Similarly, a systematic quality assessment and meta-analysis conducted by McAlindon
also found glucosamine and chondroitin to demonstrate moderate to large effects in decreasing
symptoms of osteoarthritis (McAlindon et al. 2000). This study included 15 double-blind,
randomized, placebo-controlled trials lasting 4 or more weeks from 1996 to June 1999. Only
those analyzing glucosamine or chondroitin for knee or hip osteoarthritis with reported
extractable data on the effect of treatment on symptoms were included. Findings may have been
exaggerated due to quality issues and likely publication bias. The authors admit that several of
the analyzed studies were conducted by manufacturers. Although the extent to which
glucosamine or chondroitin was effective is unknown, this study has enough evidence to
suggests that glucosamine and chondroitin does exhibit some effectiveness in decreasing
symptoms of osteoarthritis.
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On the other hand, a study conducted by Kwoh concluded that there are no structural
benefits of glucosamine supplementation particularly in individuals with chronic knee pain
(Kwoh et al. 2014). This randomized, placebo-controlled clinical trial, included 201 participants
with mild-to-moderate pain in one or both knees, as defined by a Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC). Participants received 1,500 mg glucosamine
hydrochloride in beverage form or a placebo beverage over the duration of 24 weeks. The
adjusted odds ratio for the likelihood of cartilage damage decreasing over 24 weeks in the
glucosamine treatment group compared to the control group was 0.938 (Kwoh et al. 2014). This
short-term study concluded that there is no evidence to support the idea that glucosamine
supplementation in individuals with chronic knee pain possesses some structural benefits.
The conclusion of the study conducted by Clegg coincides with those from the Kwoh et
al. (2014) study. A total of 1,583 patients with symptomatic knee osteoarthritis participated in
this study. Patients were randomly assigned to one of five groups where they could receive 1,500
mg of glucosamine daily or 1,200 mg of chondroitin sulfate daily or both glucosamine and
chondroitin sulfate or 200 mg of celecoxib daily or placebo for 24 weeks (Clegg et al. 2006).
This study found that the use of glucosamine and chondroitin sulfate, alone or in combination,
were not significantly better than placebo in reducing knee pain by 20 percent.
While there are several clinical trials and systematic reviews on glucosamine and/or
chondroitin and arthritis, observational studies are scarce. An observational study by Jawahar et
al. (2012) found that the use of complementary and alternative medicine (CAM) either alone or
in combination with prescription medicine was common among individuals with knee
osteoarthritis. Findings from this study also suggest that glucosamine and/or chondroitin use
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does not differ by gender among complementary and alternative medicine users (Jawahar et al.
2012).
Additional studies and analyses are needed to better understand socio-demographic
characteristics of adults with arthritis who use glucosamine and/or chondroitin. Determining
whether the use of these supplements result in self-reported improved health and decreased joint
pain, aching, and stiffness when compared to those who do not use these supplements are
important. This study utilizes 2012 National Health Interview Survey (NHIS) data to provide
cross-sectional analyses. The association of glucosamine and/or chondroitin use one or more
times within the past 12 months and reports of improved health when compared to 12 months
ago is one relationship that will be analyzed. The association between glucosamine and/or
chondroitin use within the past 30 days and self-reported symptoms of joint pain, aching, and
stiffness in the past 30 days will also be analyzed. While previous clinical studies have included
ways to account for the effect that dose may have in such associations, this study will analyze
glucosamine and/or chondroitin use as a four level variable: glucosamine only, chondroitin only,
neither glucosamine nor chondroitin, and both glucosamine and chondroitin.
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CHAPTER III
METHODOLOGY
DATA SOURCE
The 2012 National Health Interview Survey (NHIS), a cross-sectional household
interview survey, was used for this study. This data source is provided through the National
Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC).
NHIS has been continuously collected since July of 1957 to provide national estimates for
healthcare utilization and access, health indicators, and health related behaviors for the U.S.
civilian noninstitutionalized residents. Participants are recruited through a cost-effective complex
sampling frame which includes multistage stratification, clustering, and differential sampling
rates. Weights are adjusted based on the 2010 U.S census data. Black, Hispanic, and Asian
persons are oversampled and Black, Hispanic, or Asian persons aged 65 years have increased
chances of being selected. Participants are drawn from each state and the District of Columbia to
be nationally representative for the U.S civilian noninstitutionalized population.
The NHIS consists of four main components that are included each year: The Household
Composition Section, the Family Core questionnaire, the Sample Child Core, and the Sample
Adult Core. The Household Composition Section asks basic demographic and relationship
information on persons within the household. Because several families can live within one
household, The Family Core questionnaire is administered to each family within a household.
This questionnaire collects information on all persons in the family on topics related to health
status, health insurance coverage, and access and utilization of health care services. The Sample
Child Core is administered to one child 17 years of age or younger if present. The Sample Adult
Core is administered to one adult 18 years of age or older. An emancipated minor is not eligible

18

to participate in the Sample Child or the Sample Adult survey. Supplemental questionnaires are
included at different time intervals. The Adult Alternative Medicine and Child Alternative
Medicine questionnaires have been included every five years since 2002. The 2012 NHIS
consisted of eight data files. Because the adult population was the population of interest for this
study, only four of the eight data files were merged: Sample Adult file, Adult Alternative
Medicine Household file, and Family file.
APPROVAL
This thesis utilizes secondary public use data and did not require Institutional Review
Board (IRB) approval. The NHIS is a preapproved data source with exempt status determined by
the Georgia State University IRB (Institutional Review Board Policies).
INCLUSION AND EXCLUSION CRITERIA
While the adult sample consisted of 34,525 persons 18 years of age and older, persons
with missing responses to any of the questions used for this analysis were excluded from the
analysis of the study, resulting in a population size of 32,385 as shown in Figure 1. Furthermore,
because the subpopulation of interest are adults with arthritis, the sample was restricted to
persons that answered “yes” to: “Have you ever been told by a doctor or other health
professional that you have some form of arthritis, rheumatoid arthritis, gout, lupus, or
fibromyalgia?” Responses of “yes” to this question will be referred to as “any arthritis”
throughout this paper. Further analysis was conducted on subpopulations of persons that
responded “arthritis” and/or “rheumatoid arthritis” to the follow up question: “You just
mentioned that you were told by a doctor or other health professional that you had some form of
arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia. Which of these were you told you
had?” A person is classified as having “unspecified arthritis” if they responded “arthritis” to the
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follow up question. Likewise, a person is classified as having “rheumatoid arthritis” if they
responded “rheumatoid arthritis” to this question. Figure 1 illustrates the three subgroups: any
arthritis, unspecified arthritis, and rheumatoid arthritis.

INDEPENDENT VARIABLES
All variables of interest were assessed through self-reported data. Use of glucosamine
and/or chondroitin was assessed over two different time intervals. The first assessment was use
within the past 12-months. The second assessment was use within the past 30 days. These
variables are used as four level variables: “no supplemental use”, “glucosamine only”,
“chondroitin only”, and “both”. A person is determined to have “no supplemental use” if they
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respond neither “glucosamine” nor “chondroitin” to: “Please tell me which of these supplements
you have taken during the past 12 months?” or “Which of these supplements have you taken
during the past 30 days?” Using these same questions, a person was determined to use
“glucosamine only” if they respond “glucosamine” but did not respond “chondroitin” to these
questions. A person was determined to use “chondroitin only” if they respond “chondroitin” but
not “glucosamine” to these questions. Finally, a person was determined to be a user of “both” if
the respond both “glucosamine” and “chondroitin” to these questions.
Demographics were placed into variable categories based on survey responses from the
Adult Sample questionnaire. Sex is used as a dichotomized variable, “men” and “women”. Age
was used as a categorical variable where categories were “18-39 years old”, “40-55 years old”,
“56-70 years old”, “70-84 years old”, and “≥85 years old.” Region, education, and race were also
categorical variables. The categories for region are “Northeast”, “Midwest”, “South”, and
“West”. Education was documented as the highest level of education achieved by a family
member. These categories are “Did Not Complete High School”, “GED”, “High School
Diploma”, “Some College, No Degree”, “Associate’s Degree”, “Bachelor's Degree”, and
“Master's, Professional, or Doctoral Degree”. Race categories are “White”, “Black/African
American”, “Hispanic/Latino”, “American Indian or Alaskan Native”, and “Asian”. Poverty
level is a calculated variable in the public release data. Because poverty level was missing about
8.2% as shown in Table 1, poverty level was used as a three level variable, “Above Poverty
Line”, “At or Below Poverty Line”, and “Unknown” to eliminate missing.
To achieve better estimates, other health conditions and BMI were also analyzed. A
dichotomized variable for other health conditions was created in which a person determined to
have “other health conditions” responded “yes” to being told by a doctor or other health
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professional that they had either diabetes (except when pregnant if female) or a heart condition.
Because BMI is a risk factor for arthritis, it is also included (CDC 2014). Because BMI is
associated with certain forms of arthritis, BMI was used as a three level variable where
categories are “≤ 24.9”, “>24.9 and <30.0”, and “≥ 30.0” to identify persons that are underweight
and normal weight, overweight, and obese.
To control for confounding with other therapies used by respondents, the following were
categorized as dichotomous variables if respondents reported the use of therapies, either
themselves or with a professional, within the past 12 months: chiropractic or osteopathic
manipulation, energy therapies, mind-body therapies, and acupuncture. In previous studies, all of
these CAM therapies were described as potentially being effective in improving health and/or
decreasing pain (Corbett et al. 2013; Wang et al. 2009; Haaz & Bartlett 2011; Thorman et al.
2010; Barsky et al. 2010). Energy therapies include the use of Yoga, Tai Chi, and Qi Gong.
Mind-body therapies include the use of Mantra Meditation, Mindful Meditation, Spiritual
Meditation, Guided Imagery, and Progressive Relaxation. While Yoga and Tai Chi are often
classified as Mind-body therapies as well, they will be considered energy therapies for this thesis
to be consistent with the 2012 NHIS classifications and to prevent Qi Gong from representing
this category alone.
DEPENDENT VARIABLES
This study has two dependent variables. The first dependent variable assessed in this
thesis is improved health in the past 12-months. A person is determined to have “improved
health” if they respond “better” to: “Compared with 12 months ago, would you say your health is
better, worse, or about the same?” Likewise, a person is determined to have “unimproved health”
if they responded “worse” or “about the same” to this question. The other dependent variable
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assessed in this thesis is joint pain, aching, and stiffness in the past 30 days. A person is
determined to have “pain” if they respond “yes” to: “During the past 30 days, have you had any
symptoms of pain, aching, or stiffness in or around a joint?” If a person answered “no” to this
question, they are then classified as having “no pain”.

Table 1: Missing Variables in the 2012 National Health Interview Survey (NHIS)
2012 NHIS Adult Sample
N= 34525
Characteristics

Not Missing

Missing

% Missing

Any Arthritis

34485

40

0.1

Unspecified Arthritis

34473

52

0.2

Rheumatoid Arthritis

34473

52

0.2

12 Month Glucosamine Use
30 Day Glucosamine Use
12 Month Chondroitin Use
30 Day Chondroitin Use

34495
34525
34495
34525

30
0
30
0

0.1
0.0
0.2
0.0

Sex

34525

0

0.0

Age

34525

0

0.0

Race/Ethnicity

33919

606

1.5

BMI

33170

1355

4.1

Education

34457

68

0.1

Poverty Level

31661

2864

8.2

Poverty Level Recode*

34525

0

0.0

Region

34525

0

0.0

Other Health Conditions

34488

37

0.1

Energy Therapies

34522

3

0.0

Acupuncture

34525

0

0.0

Mind-Body Therapies

34524

1

0.0

Chiropractic/ Osteopathic Therapy

34521

4

0.2

Total**

32385

2140

6.0

*Poverty was recoded from a bivariate to a three level variable to eliminate missing.
**The calculated total uses the recoded variable of poverty level. It is important to note that this total is
not a simple tally of all missing variables but a count of all persons with at least one missing variable.
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DATA ANALYSIS
All analyses for this study were conducted using Statistical Analysis System 9.4 (SAS
9.4). The analysis accounted for the survey design and nonresponse using SAS survey
procedures. All estimates were weighted to the U.S. population to generate nationally
representative estimates based on 2010 U.S. census data.
Descriptive statistics were used to summarize characteristics that are potential risk or
protective factors for arthritis. Frequency distributions are used to identify the proportion of the
2012 National Health Interview Survey (NHIS) population that has any arthritis, unspecified
arthritis, and rheumatoid arthritis. It is also used to identify glucosamine and/or chondroitin use
within the past 12 months and within the past 30 days of the administration of the 2012 NHIS
among these subgroups.
Logistic regressions were used to conduct bivariate analyses of selected characteristics
and reports of improved health over a 12 month period among persons with each any arthritis,
unspecified arthritis, and rheumatoid arthritis. Logistic regressions were also used to conduct
bivariate analyses of selected characteristics and reports of joint pain, aching, and stiffness in the
past 30 days among persons with each any arthritis, unspecified arthritis, and rheumatoid
arthritis. Because chondroitin only and both glucosamine and chondroitin use within the past 30
days among persons with rheumatoid arthritis was unable to be observed due to small sample
size, past 30 day glucosamine use was modeled as a bivariate variable: “no glucosamine use” and
“glucosamine use”. All of these analyses were then used to identify possible confounding.
Logistic multivariate regression models were built using all selected CAM therapies
(energy therapies, acupuncture, mind-body therapies, chiropractic/osteopathic therapy) and
demographics that yielded statistically significant odds ratios in the bivariate analyses. The level
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of significance was alpha= 0.05. Different models were fit to quantify the associations of
glucosamine and/or chondroitin use within the past 12 months and self-reported improved health
when compared to 12 months ago among persons with each any arthritis, unspecified arthritis,
and rheumatoid arthritis. The same was done to quantify the associations of glucosamine and/or
chondroitin use within the past 30 days and reports of joint pain, aching, or stiffness in or around
a joint over the past 30 days among persons with each any arthritis, unspecified arthritis. Due to
the small sample size of chondroitin only and both glucosamine and chondroitin use within the
past 30 days among persons with rheumatoid arthritis, past 30 day glucosamine use was
dichotomized as: “no glucosamine use” and “glucosamine use”.
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CHAPTER IV
RESULTS
DESCRIPTIVE STATISTICS
Approximately 21.8% of the U.S population had any arthritis in 2012 (Table 2); 17% had
unspecified arthritis and 2.5% reported having rheumatoid arthritis. Women were more likely
than men to report some form of arthritis. Approximately 25% of women reported having any
arthritis, 19.7% reported having unspecified arthritis, and 3.2% reported having rheumatoid
arthritis when compared to 18.4% of any arthritis, 14.2% unspecified arthritis and 1.7%
rheumatoid arthritis among men. As can be seen in Table 2, prevalence of any arthritis,
unspecified arthritis, and rheumatoid arthritis increases with age and BMI. In addition, persons
with diabetes and/or heart conditions (other health conditions) had prevalence rates of some form
of arthritis more than twice of that of persons who did not have other health conditions. Persons
with other health conditions had a 44.2% prevalence of any arthritis, 34.8% of unspecified
arthritis, and 5.4% of and rheumatoid arthritis. Persons that did not have other health conditions
had a prevalence rate of 17.7% of any arthritis, 13.7% of unspecified arthritis, and 1.9% of
rheumatoid arthritis.
Table 2: Prevalence and Demographic Characteristics of Sample Adults Ages 18+ with Any Arthritis, Unspecified Arthritis, and
Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS)
Adult Population
N= 32385
No Unspecified
Unspecified
No Rheumatoid
Rheumatoid
Characteristics
No Arthritis Any Arthritis
Arthritis
Arthritis
Arthritis
Arthritis
n (% )
n (%)
n (%)
n (%)
n (%)
n (%)
Total
24731 (78.2) 7654 (21.8)
26369 (83.0)
6016 (17.0)
31487 (97.5)
898 (2.5)
Sex
Men
11735 (81.6) 2889 (18.4)
12377 (85.8)
2247 (14.2)
14340 (98.3)
284 (1.7)
Women
12996 (75.0) 4765 (25.0)
13992 (80.3)
3769 (19.7)
17147 (96.8)
614 (3.2)
Age
18-39 years old
11019 (94.5)
662 (5.5)
11242 (96.3)
439 (3.7)
11594 (99.2)
87 (0.8)
40-55 years old
7003 (80.0)
1826 (20.0)
7492 (85.3)
1337 (14.7)
8582 (97.3)
247 (2.7)
56-70 years old
4472 (60.0)
3030 (40.0)
5068 (67.8)
2434 (32.2)
7157 (95.9)
345 (4.1)
71-84 years old
1819 (52.5)
1669 (47.5)
2082 (60.3)
1406 (39.7)
3320 (95.4)
168 (4.6)
>85 years old
418 (47.4)
467 (52.6)
485 (55.2)
400 (44.8)
834 (94.5)
51 (5.5)
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Race/Ethnicity
White
14261 (75.0) 5346 (25.0)
15444 (80.2)
Black/African American
3614 (78.9)
1248 (21.1)
3917 (84.1)
Hispanic/Latino
4808 (88.1)
777 (11.9)
4990 (91.1)
American Indian or Alaskan Native 1799 (89.9)
234 (10.1)
1853 (92.3)
Asian
149 (76.0)
49 (24.0)
165 (84.7)
BMI
≤ 24.9
9781 (84.8)
2051 (15.2)
10205 (88.1)
>24.9 and <30.0
8588 (78.1)
2629 (21.9)
9137 (82.8)
≥ 30.0
6362 (69.8)
2974 (30.2)
7027 (76.6)
Education
Did Not Complete High School
2488 (75.2)
986 (24.8)
2652 (79.1)
GED
549 (72.4)
221 (27.6)
605 (79.8)
High School Diploma
4630 (74.9)
1698 (25.1)
5003 (80.3)
Some College, No Degree
4941 (77.3)
1554 (22.7)
5273 (82.3)
Associate’s Degree
3138 (75.8)
998 (24.2)
3378 (82.0)
Bachelor's Degree
5411 (83.0)
1242 (17.0)
5673 (86.4)
Master's, Professional, or
3574 (80.2)
955 (19.8)
3785 (84.9)
Doctoral Degree
Poverty Level
Above Poverty Line
18603 (78.2) 5753 (21.8)
19833 (82.9)
Below Poverty Line
4305 (79.7)
1254 (20.3)
4594 (84.6)
Unknown
1823 (76.2)
647 (23.8)
1942 (80.6)
Region
Northeast
4131 (79.2)
1281 (20.8)
4394 (83.6)
Midwest
5057 (76.0)
1712 (24.1)
5385 (80.7)
South
8907 (77.6)
2924 (22.4)
9566 (82.7)
West
6636 (80.6)
1737 (19.4)
7024 (85.3)
No Other Health Conditions
21703 (82.3) 5092 (17.7)
22789 (86.3)
Other Health Conditions
3028 (55.8)
2562 (44.2)
3580 (65.2)
No Energy Therapies
22265 (77.8) 7073 (22.2)
23778 (82.7)
Energy Therapies
2466 (81.9)
581 (18.1)
2591 (85.6)
No Acupuncture
24349 (78.4) 7456 (21.6)
25945 (83.1)
Acupuncture
382 (66.7)
198 (33.3)
424 (74.3)
No Mind-Body Therapies
23729 (78.5) 7234 (21.5)
25261 (83.2)
Mind-Body Therapies
1002 (71.1)
420 (28.9)
1108 (78.9)
No Chiropractic/ Osteopathic Therapy 22755 (78.9) 6780 (21.1)
24223 (83.6)
Chiropractic/ Osteopathic Therapy
1976 (71.1)
874 (28.9)
2146 (76.7)
12 Month Supplement Use:
Neither
24127 (79.1) 7142 (20.9)
25679 (83.8)
Glucosamine Only
347 (56.8)
267 (43.2)
407 (66.2)
Chondroitin Only
44 (57.8)
26 (42.2)
46 (61.2)
Both
213 (47.8)
219 (52.2)
237 (53.8)
30 Day Supplement Use:
Neither
24229 (78.9) 7244 (21.1)
25798 (83.6)
Glucosamine Only
353 (48.8)
339 (51.2)
405 (56.1)
Chondroitin Only
121 (71.8)
45 (28.2)
131 (78.7)
Both
28 (57.9)
26 (42.1)
35 (68.6)
*This table presents unweighted frequencies and weighted row percentages.
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4263 (19.8)
945 (15.9)
595 (8.9)
180 (7.7)
33 (15.3)

19175 (97.5)
4657 (96.4)
5451 (97.8)
2017 (99.1)
187 (94.5)

532 (2.5)
205 (3.6)
134 (2.2)
16 (0.9)
11 (5.5)

1627 (11.9)
2080 (17.2)
2309 (23.4)

11586 (98.2)
10940 (97.8)
8961 (96.3)

246 (1.8)
277 (2.2)
375 (3.7)

822 (20.9)
165 (20.2)
1325 (19.7)
1222 (17.7)
758 (18.0)
980 (13.6)
744 (15.1)

3348 (96.6)
733 (95.5)
6114 (96.9)
6310 (97.4)
3999 (96.7)
6540 (98.6)
4443 (98.2)

126 (3.4)
37 (4.5)
214 (3.1)
185 (2.6)
137 (3.3)
113 (1.4)
86 (1.8)

4523 (17.1)
965 (15.4)
528 (19.4)

23730 (97.6)
5353 (96.9)
2404 (97.5)

626 (2.4)
206 (3.1)
66 (2.5)

1018 (16.4)
1384 (19.3)
2265 (17.3)
1349 (14.7)
4006 (13.7)
2010 (34.8)
5560 (17.3)
456 (14.4)
5860 (16.9)
156 (25.7)
5702 (16.8)
314 (21.1)
5312 (16.4)
704 (23.3)

5255 (97.5)
6595 (97.6)
11467 (97.4)
8170 (97.7)
26233 (98.1)
5254 (94.6)
28498 (97.4)
2989 (98.4)
30931 (97.5)
556 (96.0)
30111 (97.6)
1376 (96.9)
28715 (97.5)
2772 (97.5)

157 (2.5)
174 (2.4)
364 (2.6)
203 (2.3)
562 (1.9)
336 (5.4)
840 (2.6)
58 (1.6)
874 (2.5)
24 (4.0)
852 (2.4)
46 (3.1)
820 (2.5)
78 (2.5)

5590 (16.2)
207 (33.8)
24 (38.8)
195 (46.2)

30424 (97.6)
582 (96.9)
67 (96.4)
414 (96.3)

845 (2.4)
32 (3.1)
3 (3.6)
18 (3.7)

5675 (16.4)
287 (43.9)
35 (21.3)
19 (31.4)

30617 (97.6)
658 (96.7)
163 (96.3)
49 (94.0)

856 (2.4)
34 (3.3)
3 (3.7)
5 (6.0)

Table 3 presents past 12 month glucosamine and/or chondroitin use among persons with
any arthritis. Approximately 3.7% of persons with any arthritis use glucosamine, 0.4% use
chondroitin, and 3.4% use both glucosamine and chondroitin. While glucosamine and both
glucosamine and chondroitin users were more likely to be women (58.9% and 59.7%
respectively), chondroitin users were more likely to be men (60.8%). Glucosamine, chondroitin,
and both glucosamine and chondroitin users were more likely to be between the ages of 56 to 70
(46.5%, 41.6%, and 57.3% respectively). Persons above the poverty line were more likely to be
supplement users than persons below the poverty line or persons whom income level is
unknown. Persons above the poverty line made up 91.3% of glucosamine use, 86.4% of
chondroitin use, and 94.2% of both glucosamine and chondroitin use. While persons in the West
made up the majority of glucosamine users (40.1%), persons in the Midwest made up the
majority of chondroitin users (50.4). Persons in the Northeast had the lowest prevalence of any
supplement use. In addition, more than a quarter of glucosamine users (27.7%) had other health
conditions (diabetes and/or heart conditions).
Table 3: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 12 Months among Sample Adult
Ages 18+ with Any Arthritis, 2012 National Health Interview Survey (NHIS)
Sample Adult with Any Arthritis
n= 7654
No Supplemental Use Glucosamine Only
Chondroitin Only
Characteristics
n (% )
n (%)
n (%)
Total
7142 (92.5)
267 (3.7)
26 (0.4)
Sex
Men
2689 (41.5)
99 (41.0)
12 (60.8)
Women
4453 (58.5)
168 (58.9)
14 (39.2)
Age
18-39 years old
628 (10.0)
22 (9.1)
0 (0.0)
40-55 years old
1702 (26.8)
72 (26.7)
7 (37.8)
56-70 years old
2776 (38.5)
119 (46.5)
11 (41.6)
71-84 years old
1582 (19.7)
48 (16.0)
7 (17.2)
>85 years old
454 (5.0)
6 (1.8)
1 (3.4)
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Both
n (%)
219 (3.4)
89 (40.3)
130 (59.7)
12 (6.8)
45 (22.3)
124 (57.3)
32 (11.9)
6 (1.7)

Race/Ethnicity
White
4926 (76.7)
Black/African American
1203 (11.6)
Hispanic/Latino
748 (8.6)
American Indian or Alaskan Native
220 (2.5)
Asian
45 (0.5)
BMI Category
≤ 24.9
1925 (25.7)
>24.9 and <30.0
2442 (35.1)
≥ 30.0
2775 (39.2)
Education
Did Not Complete High School
973 (8.9)
GED
218 (2.6)
High School Diploma
1625 (21.3)
Some College, No Degree
1450 (20.8)
Associate’s Degree
912 (15.0)
Bachelor's Degree
1127 (17.6)
Master's, Professional, or Doctoral Degree
837 (13.8)
Poverty Level
Above Poverty Line
5291 (78.7)
Below Poverty Line
1227 (12.6)
Unknown
624 (8.6)
Region
Northeast
1219 (17.7)
Midwest
1583 (24.8)
South
2801 (38.5)
West
1539 (19.0)
Other Health Conditions
2433 (32.3)
Energy Therapies
483 (7.0)
Acupuncture
165 (2.1)
Mind-Body Therapies
352 (5.0)
Chiropractic/ Osteopathic Therapy
758 (11.0)
*This table presents unweighted frequencies and weighted column percentages.

206 (83.4)
29 (8.8)
18 (5.0)
11 (2.5)
3 (0.3)

23 (93.0)
1 (3.3)
2 (3.7)
0 (0.0)
0 (0.0)

191 (91.0)
15 (4.2)
9 (3.1)
3 (1.3)
1 (0.5)

74 (28.1)
95 (35.8)
98 (36.0)

6 (18.7)
9 (38.7)
11 (42.6)

46 (20.0)
83 (34.3)
90 (45.7)

8 (1.4)
2 (0.1)
47 (16.4)
61 (20.8)
39 (16.1)
55 (21.1)
55 (24.0)

1 (1.9)
0 (0.0)
3 (8.9)
5 (17.2)
6 (29.4)
4 (18.9)
7 (23.7)

4 (1.7)
1 (0.6)
23 (10.9)
38 (14.7)
41 (22.2)
56 (26.4)
56 (23.5)

239 (91.3)
17 (5.7)
11 (3.0)

22 (86.4)
3 (10.2)
1 (3.4)

201 (94.2)
7 (1.5)
11 (4.3)

33 (10.5)
65 (29.0)
58 (20.4)
111 (40.1)
71 (27.7)
45 (18.3)
21 (8.3)
34 (13.1)
56 (22.5)

2 (12.4)
11 (50.4)
7 (28.6)
6 (8.5)
5 (8.2)
6 (21.5)
2 (12.7)
3 (12.6)
5 (23.2)

27 (14.5)
53 (29.9)
58 (29.0)
81 (26.6)
53 (19.1)
47 (21.4)
10 (4.7)
31 (14.0)
55 (24.8)

Table 4 presents past 12 month glucosamine and/or chondroitin use among persons with
unspecified arthritis. Approximately 3.7% of persons with unspecified arthritis were glucosamine
users, 0.5% were chondroitin users, and 3.8% were both glucosamine and chondroitin users.
Similar to among persons with any arthritis, among persons with unspecified arthritis,
glucosamine and both glucosamine and chondroitin users were more likely to be women (60.7%
and 61.9% respectively) than men. Men were more likely to be chondroitin users (57.3). Persons
ages 56-70 years of age made up a large proportion of supplement used (49.1% glucosamine use,
45.2% chondroitin use, and 60.7% both glucosamine and chondroitin use). More than half
(54.9%) of the proportion of chondroitin users were from the Midwest.
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Table 4: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 12 Months among Sample Adult
Ages 18+ with Unspecified Arthritis, 2012 National Health Interview Survey (NHIS)
Sample Adult with Unspecified Arthritis
n= 6016
No Supplemental Use
Glucosamine Only
Chondroitin Only
Characteristics
n (% )
n (%)
n (%)
Total
5590 (92.0)
207 (3.7)
24 (0.5)
Sex
Men
2087 (41.2)
74 (39.3)
10 (57.3)
Women
3503 (58.8)
133 (60.7)
14 (42.7)
Age
18-39 years old
418 (8.5)
11 (6.1)
0 (0.0)
40-55 years old
1243 (25.3)
52 (26.0)
6 (33.2)
56-70 years old
2207 (39.5)
101 (49.1)
11 (45.2)
71-84 years old
1332 (21.2)
38 (16.6)
6 (17.8)
>85 years old
390 (5.5)
5 (2.2)
1 (3.7)
Race/Ethnicity
White
3909 (77.7)
161 (84.1)
22 (93.2)
Black/African American
907 (11.1)
23 (9.5)
1 (3.6)
Hispanic/Latino
574 (8.2)
12 (4.1)
1 (3.2)
American Indian or Alaskan Native
170 (2.5)
9 (2.2)
0 (0.0)
Asian
30 (0.4)
2 (0.1)
0 (0.0)
BMI Category
≤ 24.9
1524 (26.0)
59 (27.9)
6 (20.3)
>24.9 and <30.0
1928 (35.2)
71 (35.4)
9 (42.1)
≥ 30.0
2138 (38.7)
77 (36.6)
9 (37.5)
Education
Did Not Complete High School
812 (9.6)
5 (0.6)
1 (2.0)
GED
163 (2.4)
1 (0.1)
0 (0.0)
High School Diploma
1264 (21.5)
36 (15.5)
2 (8.8)
Some College, No Degree
1136 (20.8)
48 (22.5)
5 (18.7)
Associate’s Degree
684 (14.2)
32 (15.6)
5 (24.1)
Bachelor's Degree
883 (17.9)
41 (22.2)
4 (20.6)
Master's, Professional, or Doctoral Degree
648 (13.5)
44 (23.5)
7 (25.8)
Poverty Level
Above Poverty Line
4137 (78.6)
186 (93.4)
21 (93.1)
Below Poverty Line
947 (12.5)
10 (2.8)
2 (3.2)
Unknown
506 (9.0)
11 (3.8)
1 (3.7)
Region
Northeast
967 (17.9)
25 (10.8)
2 (13.5)
Midwest
1269 (25.4)
56 (32.2)
11 (54.9)
South
2167 (38.3)
38 (16.6)
6 (23.2)
West
1187 (18.4)
88 (40.4)
5 (8.4)
Other Health Conditions
1904 (32.7)
55 (26.7)
4 (8.1)
Energy Therapies
372 (7.1)
37 (18.5)
6 (23.4)
Acupuncture
131 (2.1)
16 (7.6)
2 (13.9)
Mind-Body Therapies
258 (4.7)
27 (11.0)
2 (5.8)
Chiropractic/ Osteopathic Therapy
604 (11.4)
47 (23.6)
5 (25.3)
*This table presents unweighted frequencies and weighted column percentages.
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Both
n (%)
195 (3.8)
76 (38.1)
119 (61.9)
10 (6.9)
36 (18.2)
115 (60.7)
30 (12.6)
4 (1.6)
171 (91.8)
14 (4.5)
8 (3.1)
1 (0.2)
1 (0.5)
38 (18.4)
72 (32.5)
85 (49.1)
4 (2.0)
1 (0.7)
23 (12.3)
33 (14.1)
37 (21.9)
52 (27.5)
45 (21.5)
179 (93.9)
6 (1.6)
10 (4.6)
24 (14.2)
48 (30.1)
54 (29.9)
69 (15.9)
47 (20.2)
41 (20.5)
7 (2.9)
27 (13.4)
48 (23.0)

Table 5 presents past 12 month glucosamine and/or chondroitin use among persons with
rheumatoid arthritis. Approximately 2.4% of persons with rheumatoid arthritis used glucosamine
while 0.3% used chondroitin, and 2.1% used both glucosamine and chondroitin. The majority of
glucosamine and both glucosamine and chondroitin use were women (59.3% and 58.0%
respectively) however; men made up 94.0% of chondroitin use. Persons 40-55 years old made up
85.1% of chondroitin use. Obese (BMI >30.0) individuals had the highest proportion of
glucosamine and chondroitin use (42.9% and 94.0% respectively). While glucosamine use and
both glucosamine and chondroitin use were most common among persons above poverty level
(83.3% and 100.0% respectively), persons below poverty level made up the highest proportion of
chondroitin use (85.1%).
Table 5: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 12 Months among Sample Adult
Ages 18+ with Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS)
Sample Adult with Rheumatoid Arthritis
n= 898
No Supplemental Use
Glucosamine Only
Chondroitin Only
Characteristics
n (% )
n (%)
n (%)
Total
845 (95.2)
32 (2.4)
13 (0.3)
Sex
Men
263 (34.2)
10 (40.7)
2 (94.0)
Women
582 (65.8)
22 (59.3)
1 (6.0)
Age
18-39 years old
81 (11.7)
4 (23.4)
0 (0.0)
40-55 years old
233 (31.1)
8 (23.1)
1 (85.1)
56-70 years old
323 (35.8)
13 (40.2)
1 (6.0)
71-84 years old
159 (16.8)
6 (12.3)
1 (8.9)
>85 years old
49 (4.6)
1 (1.0)
0 (0.0)
Race/Ethnicity
White
495 (67.0)
21 (64.5)
2 (91.1)
Black/African American
199 (17.0)
5 (16.6)
0 (0.0)
Hispanic/Latino
128 (13.4)
4 (15.3)
1 (8.9)
American Indian or Alaskan Native
13 (1.5)
1 (1.1)
0 (0.0)
Asian
10 (1.0)
1 (2.5)
0 (0.0)
BMI Category
≤ 24.9
233 (26.7)
7 (21.6)
0 (0.0)
>24.9 and <30.0
257 (30.7)
13 (35.5)
1 (6.0)
≥ 30.0
355 (42.6)
12 (42.9)
2 (94.0)
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Both
n (%)
18 (2.1)
9 (42.0)
9 (58.0)
2 (9.6)
5 (44.1)
8 (37.8)
2 (7.6)
1 (1.0)
14 (75.7)
1 (2.8)
1 (5.4)
2 (16.1)
0 (0.0)
6 (39.0)
6 (33.2)
6 (27.7)

Education
Did Not Complete High School
123 (10.1)
GED
36 (3.6)
High School Diploma
208 (23.4)
Some College, No Degree
171 (20.9)
Associate’s Degree
129 (18.0)
Bachelor's Degree
105 (12.8)
Master's, Professional, or Doctoral Degree
73 (11.0)
Poverty Level
Above Poverty Line
578 (76.1)
Below Poverty Line
201 (16.0)
Unknown
66 (7.9)
Region
Northeast
151 (19.0)
Midwest
164 (21.4)
South
351 (39.4)
West
179 (20.2)
Other Health Conditions
321 (35.1)
Energy Therapies
49 (5.3)
Acupuncture
19 (1.9)
Mind-Body Therapies
40 (4.6)
Chiropractic/ Osteopathic Therapy
63 (7.7)
*This table presents unweighted frequencies and weighted column percentages.

3 (12.8)
1 (1.2)
5 (14.2)
12 (29.1)
4 (17.6)
4 (14.9)
3 (10.4)

0 (0.0)
0 (0.0)
1 (8.9)
0 (0.0)
1 (85.1)
0 (0.0)
1 (6.0)

0 (0.0)
0 (0.0)
0 (0.0)
2 (8.6)
3 (31.9)
4 (26.3)
9 (33.3)

28 (83.3)
4 (16.7)
0 (0.0)

2 (14.9)
1 (85.1)
0 (0.0)

18 (100.0)
0 (0.0)
0 (0.0)

4 (7.7)
4 (20.8)
11 (39.4)
13 (32.1)
9 (20.7)
3 (12.1)
2 (7.6)
3 (9.2)
7 (22.7)

0 (0.0)
0 (0.0)
1 (85.1)
2 (14.9)
2 (14.9)
1 (6.0)
0 (0.0)
1 (85.1)
0 (0.0)

2 (6.3)
6 (52.6)
1 (3.7)
9 (29.3)
4 (12.1)
5 (40.6)
3 (29.5)
2 (25.7)
8 (53.5)

Table 6 presents past 30 day glucosamine and/or chondroitin use among persons with any
arthritis. Approximately 5.1% of persons with any arthritis used glucosamine, 0.6% used
chondroitin, and 0.4% used both glucosamine and chondroitin within the past 30 days. As
presented in Table 6, women made up the majority of all past 30 day supplement use (59.3%
glucosamine, 76.6% chondroitin, and 63.4% both glucosamine and chondroitin). Persons 56 to
70 years old had the highest proportion of all past 30 day supplement use (55.7% glucosamine,
57.7% chondroitin, and 39.2% both glucosamine and chondroitin). White people also made up
the majority of all past 30 day supplement use (90.3% glucosamine, 81.9% chondroitin, and
72.4% both glucosamine and chondroitin). Persons above poverty level also made up the
majority of all past 30 day supplement use (92.1% glucosamine, 80.2% chondroitin, and 96.7%
both glucosamine and chondroitin).
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Table 6: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 30 Days among Sample Adult Ages
18+ with Any Arthritis, 2012 National Health Interview Survey (NHIS)
Sample Adult with Any Arthritis
n= 7654
No Supplemental Use
Glucosamine Only
Chondroitin Only
Both
Characteristics
n (% )
n (%)
n (%)
n (%)
Total
7244 (94.0)
339 (5.1)
45 (0.6)
26 (0.4)
Sex
Men
Women
Age
18-39 years old
40-55 years old
56-70 years old
71-84 years old
>85 years old
Race/Ethnicity
White
Black/African American
Hispanic/Latino
American Indian or
Alaskan Native
Asian
BMI Category
≤ 24.9
>24.9 and <30.0
≥ 30.0
Education
Did Not Complete High School
GED
High School Diploma
Some College, No Degree
Associate’s Degree
Bachelor's Degree
Master's, Professional, or Doctoral Degree

2738 (41.7)
4506 (58.3)

132 (40.7)
207 (59.3)

11 (23.4)
34 (76.6)

8 (36.6)
18 (63.4)

640 (10.0)
1734 (27.0)
2821 (38.5)
1593 (19.5)
456 (5.0)

13 (5.0)
72 (20.9)
177 (55.7)
67 (16.5)
10 (1.9)

6 (9.6)
12 (21.0)
21 (57.7)
6 (11.7)
0 (0.0)

3 (11.1)
8 (28.6)
11 (39.2)
3 (18.4)
1 (2.7)

5012 (76.8)
1213 (11.6)
751 (8.5)
222 (2.5)

282 (90.3)
22 (4.1)
21 (4.0)
11 (1.3)

33 (81.9)
7 (7.6)
5 (10.5)
0 (0.0)

19 (72.4)
6 (25.4)
0 (0.0)
1 (2.1)

46 (0.5)

3 (0.2)

0 (0.0)

0 (0.0)

1948 (25.5)
2476 (35.1)
2820 (39.4)

84 (26.1)
127 (34.6)
128 (39.3)

11 (33.3)
15 (23.6)
19 (43.1)

8 (19.0)
11 (55.7)
7 (25.3)

973 (8.7)
216 (2.5)
1636 (21.1)
1474 (20.8)
930 (15.1)
1156 (17.7)
859 (14.0)

7 (1.2)
2 (0.5)
53 (15.6)
65 (16.8)
62 (20.5)
68 (22.2)
82 (23.2)

3 (4.9)
3 (3.5)
5 (12.9)
9 (21.2)
6 (13.5)
8 (20.0)
11 (23.8)

3 (6.7)
0 (0.0)
4 (17.8)
6 (17.8)
0 (0.0)
10 (32.0)
3 (25.8)

Poverty Level
Above Poverty Line
Below Poverty Line
Unknown

5388 (79.0)
1230 (12.5)
626 (8.5)

308 (92.1)
14 (3.6)
17 (4.3)

33 (80.2)
9 (15.0)
3 (4.8)

24 (96.7)
1 (0.6)
1 (2.7)

Region
Northeast
Midwest
South
West
Other Health Conditions
Energy Therapies
Acupuncture
Mind-Body Therapies

1231 (17.5)
1612 (25.0)
2822 (38.4)
1579 (19.1)
2459 (32.2)
509 (7.3)
171 (2.2)
365 (5.2)

44 (14.5)
83 (30.8)
80 (22.3)
132 (32.5)
86 (22.9)
52 (15.5)
18 (5.9)
40 (11.6)

2 (6.5)
12 (34.9)
15 (31.0)
16 (27.6)
13 (20.2)
11 (34.7)
5 (9.3)
9 (21.2)

4 (9.1)
5 (12.9)
7 (29.0)
10 (49.1)
4 (28.6)
9 (47.4)
4 (16.7)
6 (28.7)

75 (23.5)

13 (22.9)

9 (35.8)

Chiropractic/ Osteopathic Therapy
777 (11.2)
*This table presents unweighted frequencies and weighted column percentages.
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Table 7 presents past 30 day glucosamine and/or chondroitin use among persons with
unspecified arthritis. Approximately 5.5% of persons with unspecified arthritis had past 30 day
use of glucosamine, 0.5% chondroitin, and 0.4% both glucosamine and chondroitin. Women
made up the majority of all supplement use (62.4% glucosamine, 69.7% chondroitin, and 56.8%
both glucosamine and chondroitin). Persons age 56 to 70 years old reported the highest
proportion of past 30 day supplement use (57.9% glucosamine, 57.1% chondroitin, 33.0% both
glucosamine and chondroitin). Supplement use was most common among white persons with
unspecified arthritis (90.9% glucosamine, 78.3% chondroitin, and 67.2% both glucosamine and
chondroitin). Persons above poverty level also had the highest proportion of all supplement use
(93.0% glucosamine, 76.6% chondroitin, and 95.5% both glucosamine and chondroitin). Persons
with unspecified arthritis in the Northeast had the lowest proportion of any supplement use
(14.7% glucosamine, 2.0% chondroitin, and 5.3% both glucosamine and chondroitin).
Table 7: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 30 Days among Sample Adult Ages
18+ with Unspecified Arthritis, 2012 National Health Interview Survey (NHIS)
Sample Adult with Unspecified Arthritis
n= 6016
No Supplemental Use
Glucosamine Only
Chondroitin Only
Characteristics
n (% )
n (%)
n (%)
Total
5675 (93.5)
287 (5.5)
35 (0.5)
Sex
Men
2125 (41.4)
106 (37.6)
10 (30.3)
Women
3550 (58.6)
181 (62.4)
25 (69.7)
Age
18-39 years old
422 (8.5)
9 (4.9)
6 (12.7)
40-55 years old
1271 (25.5)
56 (18.3)
7 (15.5)
56-70 years old
2249 (39.6)
158 (57.9)
17 (57.1)
71-84 years old
1341 (20.9)
57 (16.9)
5 (14.8)
≥ 85 years old
392 (5.5)
7 (2.0)
0 (0.0)
Race/Ethnicity
White
3984 (77.9)
242 (90.9)
24 (78.3)
Black/African American
915 (11.1)
19 (4.3)
6 (7.7)
Hispanic/Latino
575 (8.1)
15 (3.3)
5 (14.0)
American Indian or Alaskan Native
170 (2.4)
9 (1.4)
0 (0.0)
Asian
31 (0.5)
2 (0.1)
0 (0.0)
BMI Category
≤ 24.9
1543 (25.8)
69 (24.3)
9 (37.4)
>24.9 and <30.0
1954 (35.2)
104 (34.6)
14 (30.5)
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Both
n (%)
19 (0.4)
6 (43.3)
13 (56.8)
2 (10.0)
3 (26.6)
10 (33.0)
3 (24.7)
1 (3.7)
13 (67.2)
5 (30.0)
0 (0.0)
1 (2.8)
0 (0.0)
6 (21.3)
8 (49.9)

≥ 25.0

2178 (39.0)

Education
Did Not Complete High School
811 (9.4)
GED
162 (2.3)
High School Diploma
1275 (21.3)
Some College, No Degree
1157 (20.8)
Associate’s Degree
698 (14.3)
Bachelor's Degree
905 (18.0)
Master's, Professional, or Doctoral Degree
667 (13.7)
Poverty Level
Above Poverty Line
4221 (80.0)
Below Poverty Line
946 (12.2)
Unknown
508 (8.8)
Region
Northeast
978 (17.8)
Midwest
1297 (25.6)
South
2182 (38.1)
West
1218 (18.6)
Other Health Conditions
1927 (32.5)
Energy Therapies
396 (7.4)
Acupuncture
133 (2.1)
Mind-Body Therapies
270 (4.9)
Chiropractic/ Osteopathic Therapy
621 (11.5)
*This table presents unweighted frequencies and weighted column percentages.

114 (41.1)

12 (32.1)

5 (28.8)

6 (1.3)
1 (0.5)
44 (14.9)
51 (16.7)
55 (19.5)
63 (24.8)
67 (22.2)

3 (6.4)
2 (1.9)
3 (6.7)
8 (27.4)
5 (11.2)
6 (19.5)
8 (26.7)

2 (6.3)
0 (0.0)
3 (22.3)
6 (23.9)
0 (0.0)
6 (30.4)
2 (17.1)

261 (93.0)
10 (2.2)
16 (4.8)

24 (76.6)
8 (17.1)
3 (6.3)

17 (95.5)
1 (0.8)
1 (3.7)

37 (14.7)
76 (32.6)
65 (21.4)
109 (31.4)
72 (22.8)
45 (15.4)
15 (5.1)
32 (9.4)
68 (24.3)

1 (2.0)
8 (30.5)
12 (32.0)
14 (35.5)
9 (20.1)
8 (38.6)
5 (12.3)
7 (21.0)
9 (19.1)

2 (5.3)
3 (14.0)
6 (37.4)
8 (43.3)
2 (19.3)
7 (41.1)
3 (17.5)
5 (21.0)
6 (22.8)

Table 8 presents past 30 day glucosamine and/or chondroitin use among persons with
rheumatoid arthritis. Approximately 2.9% of persons with rheumatoid arthritis had past 30 day
use of glucosamine, 0.7% chondroitin, and 0.5% both glucosamine and chondroitin. Persons 18
to 39 years old reported the largest proportion of both glucosamine and chondroitin use. Persons
56 to 70 years old reported the largest proportion of glucosamine use (42.9%) and chondroitin
use (85.8%). Persons above poverty level also had the highest proportion of all supplement use
(95.7% glucosamine, 100.0% chondroitin, and 100.0 both glucosamine and chondroitin). A large
proportion of persons that reported past 30 day chondroitin use were from the Midwest (60.9%).
Nearly half of the proportion of persons with rheumatoid arthritis that reported use of
chiropractic/osteopathic therapy reported past 30 day use of chondroitin (46.7%) and both
glucosamine and chondroitin (52.9%).
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Table 8: Demographic Characteristics of Glucosamine and/or Chondroitin Use within the Past 30 Days among Sample Adult Ages 18+ with
Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS)
Sample Adult with Rheumatoid Arthritis
n= 898
No Supplemental Use
Glucosamine Only
Chondroitin Only
Both
Characteristics
n (% )
n (%)
n (%)
n (%)
Total
Sex
Men
Women
Age
18-39 years old
40-55 years old
56-70 years old
71-84 years old
≥ 85 years old
Race/Ethnicity
White
Black/African American
Hispanic/Latino
American Indian or Alaskan Native
Asian

856 (96.0)

34 (2.9)

3 (0.7)

5 (0.5)

270 (34.9)
586 (65.1)

12 (29.7)
22 (70.2)

0 (0.0)
3 (100.0)

2 (65.2)
3 (34.8)

83 (11.9)
236 (31.4)
328 (35.4)
160 (16.7)
49 (4.6)

2 (4.6)
8 (35.4)
14 (42.9)
8 (15.7)
2 (1.5)

0 (0.0)
1 (14.2)
2 (85.8)
0 (0.0)
0 (0.0)

2 (65.2)
2 (22.1)
1 (12.7)
0 (0.0)
0 (0.0)

502 (66.8)
201 (17.0)
129 (13.3)
14 (1.8)
10 (1.0)

24 (74.6)
2 (4.7)
5 (16.4)
2 (2.2)
1 (2.0)

2 (85.8)
1 (14.2)
0 (0.0)
0 (0.0)
0 (0.0)

4 (87.3)
1 (12.7)
0 (0.0)
0 (0.0)
0 (0.0)

9 (33.4)
13 (26.6)
12 (40.0)

1 (39.1)
0 (0.0)
2 (60.9)

2 (22.1)
2 (38.9)
1 (39.0)

1 (1.2)
1 (1.0)
3 (8.2)
10 (23.6)
6 (33.0)
3 (5.8)
10 (27.3)

0 (0.0)
0 (0.0)
1 (46.7)
1 (14.2)
0 (0.0)
1 (39.1)
0 (0.0)

1 (14.0)
0 (0.0)
2 (20.8)
0 (0.0)
0 (0.0)
2 (65.2)
0 (0.0)

32 (95.7)
2 (4.3)
0 (0.0)

3 (100.0)
0 (0.0)
0 (0.0)

5 (100.0)
0 (0.0)
0 (0.0)

5 (14.6)
7 (37.6)
7 (19.5)
15 (28.3)
10 (19.4)
5 (26.0)
2 (17.4)
3 (22.0)
5 (23.5)

0 (0.0)
2 (60.9)
1 (39.1)
0 (0.0)
0 (0.0)
1 (39.1)
1 (14.2)
0 (0.0)
1 (46.7)

1 (14.0)
0 (0.0)
3 (59.9)
1 (26.1)
1 (8.1)
1 (26.1)
1 (26.1)
1 (12.7)
3 (52.9)

BMI Category
≤ 24.9
234 (26.5)
>24.9 and <30.0
262 (31.1)
≥ 30.0
360 (42.4)
Education
Did Not Complete High School
124 (10.3)
GED
36 (3.6)
High School Diploma
208 (23.0)
Some College, No Degree
174 (20.9)
Associate’s Degree
131 (18.3)
Bachelor's Degree
107 (12.9)
Master's, Professional, or Doctoral Degree
76 (11.1)
Poverty Level
Above Poverty Line
586 (75.7)
Below Poverty Line
204 (16.4)
Unknown
66 (7.9)
Region
Northeast
151 (18.8)
Midwest
165 (21.3)
South
353 (39.3)
West
187 (20.6)
Other Health Conditions
325 (35.0)
Energy Therapies
51 (5.3)
Acupuncture
20 (2.0)
Mind-Body Therapies
42 (4.9)
Chiropractic/ Osteopathic Therapy
69 (8.1)
*This table presents unweighted frequencies and weighted column percentages.
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BIVARIATE ANALYSES
Table 9 presents odds ratios, 95% Confidence intervals (95% CI), and p-values for
selected characteristics and self-reported past 12 month improved health among persons with any
arthritis, unspecified arthritis, and rheumatoid arthritis. Age, sex, and region were demographic
characteristics that yielded statistically significant associations with self-reported past 12 month
improved health among persons with any arthritis. When compared to persons 18 to 39 years old,
persons 40 to 55 years old were 0.6 times likely to report improved health (OR= 0.6; p= 0.04),
persons 71 to 84 years old were 0.4 times likely to report improved health (OR= 0.4; p= 0.01),
and persons 85 years old and older were 0.2 times likely to report improved health (OR= 0.2; p=
<0.01) among persons with any arthritis. Men were 0.8 times likely to report improved health
when compared to women (OR= 0.8; p= 0.02). Persons in the West were 1.3 times likely to
report improved health when compared to persons in the Northeast (OR=1.3; p= 0.01).
All other observed CAM therapies (acupuncture, energy, chiropractic/osteopathic, and
mind-body therapies), were shown to be associated with self-reported past 12 month improved
health among persons with any arthritis. Persons that saw an acupuncturist one of more times
within the 12 months prior to survey administration were 1.9 times likely to report improved
health when compared to persons that has not seen an acupuncturist (OR= 1.9; p= <0.01).
Persons that engaged in energy therapies one or more times within the 12 months prior to taking
the survey were 2.2 times likely to report improved health when compared to persons that never
engaged in energy therapy (OR= 2.2; p= <0.01) among persons with any arthritis. Persons that
engaged in a mind-body therapy one or more times within the 12 months prior to the
administration of the survey were also 2.2 times likely to report improved health when compared
to persons that never engaged in an energy therapy (OR=2.2; p= <0.01). Persons that saw a

37

chiropractor one of more times within the 12 months prior to survey administration were 1.4
times likely to report improved health when compared to persons that did not (OR= 1.4; p=
<0.01).
Sex, age, BMI, and education were demographic characteristics that yielded statistically
significant associations with self-reported past 12 month improved health among persons with
unspecified arthritis, as seen in Table 9. Men were 0.8 times likely to report improved health
than women (OR= 0.8; p= 0.02). When compared to persons 18 to 39 years old, persons 71 to 84
years old were 0.3 times likely to report improved health (OR= 0.3; p= <0.01) and persons 85
years and older were 0.2 times likely to report improved health (OR= 0.2; p= <0.01). Obese
(BMI ≥ 30) persons with unspecified arthritis were 1.3 times likely to report improved health
than persons that were either underweight or normal weight (OR= 1.3; p= 0.01). When compared
to persons that did not complete high school, persons with a high school diploma were 0.9 times
likely to report improved health (OR= 0.9; p= <0.01), persons with some college were 1.5 times
likely to report improved health (OR= 1.5; p= 0.02), and persons with an associate’s degree 1.6
times likely to report improved health (OR= 1.6; p= 0.04).
As can be seen in Table 9, all other observed CAM therapies (acupuncture, energy,
chiropractic/osteopathic, and mind-body therapies) were shown to be associated with selfreported past 12 month improved health among persons with unspecified arthritis. Persons who
saw an acupuncturist one of more times within the 12 months prior to survey administration were
1.8 times likely to report improved health when compared to persons that has not seen an
acupuncturist (OR= 1.8; p= 0.01). Persons that engaged in energy therapies one or more times
within the 12 months prior to taking the survey were 2.1 times likely to report improved health
when compared to persons that never engaged in an energy therapy during this period (OR= 2.1;
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p= <0.01). Persons that engaged in mind-body therapy one or more times within the 12 months
prior to the administration of the survey were also 2.2 times likely to report improved health
when compared to persons that never engaged in a mind-body therapy during this period
(OR=2.2; p= <0.01). Persons that saw a chiropractor one of more times within the 12 months
prior to survey administration were 1.3 times likely to report improved health when compared to
persons that did not (OR= 1.3; p= 0.01).
While no demographic characteristics yielded statistically significant associations with
self-reported past 12 month improved health among persons with rheumatoid arthritis, all other
observed CAM therapies (acupuncture, energy, chiropractic/ osteopathic, and mind-body
therapies) did, as seen in Table 9. Persons who saw an acupuncturist one of more times within
the 12 months prior to survey administration were 4.6 times likely to report improved health
when compared to persons that had not (OR= 4.6; p= <0.01). Persons that engaged in an energy
therapy one or more times within the 12 months prior to taking the survey were 2.7 times likely
to report improved health when compared to persons that had not (OR= 2.7; p= 0.01). Persons
that engaged in a mind-body therapy one or more times within the 12 months prior to the
administration of the survey were also 2.7 times likely to report improved health when compared
to persons that never engaged in an mind-body therapy during this period (OR=2.7; p= <0.01).
Persons that saw a chiropractor one of more times within the 12 months prior to survey
administration were 2.5 times likely to report improved health when compared to persons that
did not (OR= 2.5; p= <0.01).
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Table 9: Bivariate Analysis of Selected Characteristics and Reports of Improved Health Over a 12 Month Period among Persons
with Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS)
Self-Reported Improved Health over a 12-Month Period
Characteristics
No Supplement Use
Glucosamine Only
Chondroitin Only
Glucosamine and Chondroitin
Sex
Women
Men
Age
18-39 years old
40-55 years old
56-70 years old
71-84 years old
>85 years old
Race/Ethnicity
White
Black/African American
Hispanic/Latino
American Indian or Alaskan Native
Asian
BMI Category
≤ 24.9
>24.9 and <30.0
≥ 30.0
Education
Did Not Complete High School
GED
High School Diploma
Some College, No Degree
Associate’s Degree
Bachelor's Degree
Master's, Professional, or Doctoral Degree
Poverty Level
Above Poverty Line
Below Poverty Line
Unknown
Region
Northeast
Midwest
South
West
No Other Health Conditions
Other Health Conditions
No Energy Therapies
Energy Therapies

Any Arthritis
n= 7654
OR (95%CI)
p-value
1.0 (referent)
1.4 (1.0-1.9)
0.07
0.7 (0.3-1.7)
0.28
1.1 (0.7-1.7)
0.67

Unspecified Arthritis
n= 6016
OR (95%CI)
p-value
1.0 (referent)
1.2 (0.8-1.8)
0.40
0.7 (0.3-1.9)
0.43
1.1 (0.7-1.7)
0.65

Rheumatoid Arthritis
n= 898
OR (95%CI)
p-value
1.0 (referent)
1.5 (0.7-3.4)
0.47
0.4 (0.1-2.8)
0.17
2.7 (0.8-9.5)
0.11

1.0 (referent)
0.8 (0.7-1.0)

0.02

1.0 (referent)
0.8 (0.7-1.0)

0.02

1.0 (referent)
1.0 (0.6-1.5)

0.86

1.0 (referent)
0.6 (0.4-0.7)
0.5 (0.4-0.7)
0.4 (0.3-0.5)
0.2 (0.1-0.4)

0.04
0.27
0.01
<0.01

1.0 (referent)
0.5 (0.4-0.7)
0.5 (0.4-0.7)
0.3 (0.2-0.5)
0.2 (0.1-0.3)

0.10
0.21
<0.01
<0.01

1.0 (referent)
0.5 (0.2-1.0)
0.5 (0.2-1.0)
0.4 (0.2-0.9)
0.1 (0.0-0.3)

0.37
0.23
0.59
<0.01

1.0 (referent)
1.1 (0.9-1.3)
1.3 (1.0-1.6)
1.1 (0.7-1.7)
1.0 (0.4-2.8)

0.98
0.28
0.99
0.89

1.0 (referent)
1.1 (0.8-1.3)
1.3 (1.0-1.6)
1.3 (0.8-2.1)
0.8 (0.2-3.5)

0.98
0.38
0.50
0.66

1.0 (referent)
1.2 (0.8-1.8)
1.1 (0.7-1.8)
0.4 (0.1-1.7)
2.8 (1.0-7.4)

0.59
0.79
0.09
0.03

1.0 (referent)
1.0 (0.8-1.2)
1.1 (0.9-1.3)

0.29
0.10

1.0 (referent)
1.0 (0.8-1.3)
1.3 (1.0-1.5)

0.42
0.01

1.0 (referent)
0.6 (0.4-1.0)
0.5 (0.3-0.9)

0.25
0.06

1.0 (referent)
0.9 (0.5-1.5)
0.9 (0.7-1.3)
1.4 (1.1-1.9)
1.6 (1.2-2.1)
1.4 (1.0-1.8)
1.5 (1.1-2.0)

0.13
<0.01
0.05
<0.01
0.15
0.04

1.0 (referent)
1.0 (0.6-1.9)
0.9 (0.7-1.3)
1.5 (1.1-2.1)
1.6 (1.1-2.2)
1.3 (1.0-1.9)
1.5 (1.1-2.0)

0.44
<0.01
0.02
0.04
0.39
0.08

1.0 (referent)
0.6 (0.2-2.0)
0.9 (0.4-1.7)
1.0 (0.5-2.0)
1.5 (0.8-2.7)
1.4 (0.5-3.4)
1.5 (0.7-2.9)

0.23
0.32
0.85
0.07
0.45
0.21

1.0 (referent)
0.9 (0.7-1.1)
0.8 (0.6-1.1)

0.28
0.30

1.0 (referent)
1.0 (0.8-1.3)
0.9 (0.6-1.2)

0.58
0.38

1.0 (referent)
0.6 (0.4-1.0)
0.7 (0.3-1.3)

0.32
0.60

1.0 (referent)
1.1 (0.8-1.4)
1.0 (0.8-1.2)
1.3 (1.0-1.6)
1.0 (referent)
1.0 (0.8-1.2)
1.0 (referent)
2.2 (1.7-2.8)

0.91
0.09
0.01
0.99
<0.01
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1.0 (referent)
1.1 (0.8-1.4)
1.0 (0.7-1.2)
1.2 (0.9-1.5)
1.0 (referent)
1.0 (0.9-1.2)
1.0 (referent)
2.1 (1.6-2.8)

0.71
0.12
0.09
0.87
<0.01

1.0 (referent)
1.1 (0.6-1.9)
0.9 (0.5-1.6)
1.5 (1.0-2.5)
1.0 (referent)
0.9 (0.6-1.3)
1.0 (referent)
2.7 (1.4-5.1)

0.83
0.25
0.02
0.42
<0.01

No Acupuncture
1.0 (referent)
Acupuncture
1.9 (1.3-2.8)
No Mind-Body Therapies
1.0 (referent)
Mind-Body Therapies
2.2 (1.7-3.0)
No Chiropractic/ Osteopathic Therapy
1.0 (referent)
Chiropractic/ Osteopathic Therapy
1.4 (1.2-1.7)
*Estimates presented were found using a logistic regression.

<0.01
<0.01
<0.01

1.0 (referent)
1.8 (1.2-2.8)
1.0 (referent)
2.2 (1.6-3.2)
1.0 (referent)
1.3 (1.1-1.7)

0.01
<0.01
0.01

1.0 (referent)
4.6 (1.8-11.5)
1.0 (referent)
2.7 (1.3-5.5)
1.0 (referent)
2.5 (1.4-4.4)

Table 10 presents odds ratios, 95% Confidence intervals (95% CI), and p-values for
selected characteristics and self-reported joint pain, aching, and stiffness within the past 30 days
prior to taking the survey among persons with any arthritis, unspecified arthritis, and rheumatoid
arthritis. Sex, age, race, BMI, poverty level, other health conditions (diabetes and/or heart
condition), and chiropractic/osteopathic therapy were characteristics that yielded statistically
significant associations with self-reported past 30 day joint pain, aching, and stiffness among
persons with any arthritis. Men were 0.9 times likely to report past 30 day joint pain, aching, and
stiffness than women (OR= 0.9; p= 0.02) among persons with any arthritis. Persons 56 to 70
years old were 1.5 times likely to report past 30 day joint pain, aching, and stiffness than persons
18 to 39 years old (OR= 1.5; p= <0.01) among persons with any arthritis. When compared to
white persons with any arthritis, Black/African Americans were 1.2 times likely to report past 30
day joint pain, aching, and stiffness (OR= 1.2; p= 0.04) and American Indian or Alaskan Native
were 0.7 times likely to report past 30 day joint pain, aching, and stiffness (OR= 0.7; p= 0.03).
Obese persons (BMI ≥ 30) were 1.8 times likely to report past 30 day joint pain, aching, and
stiffness than persons either underweight or normal weight (BMI< 25) (OR= 1.8; p= <0.01).
Persons below the poverty line were 1.3 time likely to report past 30 day joint pain, aching, and
stiffness than persons above the poverty line (OR= 1.3; p= 0.04). Persons with other health
conditions (diabetes and heart conditions) were 1.4 times likely to report past 30 day joint pain,
aching, and stiffness than persons without other health conditions (OR= 1.4; p= <0.01). Persons
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<0.01
0.01
<0.01

that saw a chiropractor one of more times within the 12 months prior to survey administration
were 1.3 times likely to report past 30 day joint pain, aching, and stiffness when compared to
persons that did not (OR= 2.5; p= <0.01).
Age, BMI, poverty level, region, other health conditions (diabetes and/or heart
condition), mind-body therapies, and chiropractic/osteopathic therapy were characteristics that
yielded statistically significant associations with self-reported past 30 day joint pain, aching, and
stiffness among persons with unspecified arthritis, as seen in Table 10. Persons 56 to 70 years of
age were 1.4 times likely to report past 30 day joint pain, aching, and stiffness than persons 18 to
39 years old (OR= 1.1; p= <0.01). Obese persons (BMI ≥ 30) were 2.0 times likely to report
BMI past 30 day joint pain, aching, and stiffness than persons underweight and normal weight
(BMI < 25) (OR= 2.0; p= <0.01). Persons below poverty level were 1.3 times likely to report
past 30 day joint pain, aching, and stiffness than persons above poverty level (OR= 1.3; p= 0.03).
Persons in the South were 1.5 times likely to report past 30 day joint pain, aching, and stiffness
than persons in the Northeast region (OR= 1.5; p= 0.01). Persons with other health conditions
(diabetes and heart conditions) were 1.6 times likely to report past 30 day joint pain, aching, and
stiffness than persons without other health conditions (OR= 1.6; p= <0.01). Persons that
reported past 12 month use of mind-body therapy were 1.4 times likely to past 30 day joint pain,
aching, and stiffness than persons that never engaged in mind-body therapy (OR=1.4; p= 0.02).
Persons that saw a chiropractor one of more times within the 12 months prior to survey
administration were 1.3 times likely to report past 30 day joint pain, aching, and stiffness when
compared to persons that did not (OR= 1.3; p= 0.03).
As shown in Table 10, only poverty level and mind-body therapies were characteristics
that yielded statistically significant associations with self-reported past 30 day joint pain, aching,
42

and stiffness among persons with unspecified arthritis, as seen in Table 10. When compared to
persons above the poverty level, persons below were 2.6 times likely to report past 30 day joint
pain, aching, and stiffness (OR= 2.6; p= <0.01), and persons whom poverty level is unknown
were 0.8 time likely to report past 30 day joint pain, aching, and stiffness (OR= 0.8; p= 0.03).
Finally, persons that engaged in mind-body therapy one or more times within the 12 months
prior to the administration of the survey were 0.4 times likely to report past 30 day joint pain,
aching, and stiffness when compared to persons that never engaged in mind-body therapy (OR=
0.4; p= 0.03).
Table 10: Bivariate Analysis of Selected Characteristics and Reports of Joint Pain, Aching, or Stiffness in or around a Joint Over the Past 30 Days
among Persons with Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis, 2012 National Health Interview Survey (NHIS)
Self-Reported Joint Pain in Past 30 Days
Any Arthritis
Unspecified Arthritis
Rheumatoid Arthritis
Characteristics
n= 7654
n= 6016
n= 898
OR (95% CI)
p-value
OR (95% CI)
p-value
OR (95% CI)
p-value
1.0 (referent)
No Supplement Use
1.0 (referent)
1.0 (referent)
1.7 (0.5-5.8)
Glucosamine Only
2.2 (1.6-3.1)
0.32
2.5 (1.7-3.7)
0.29
0.43
-Chondroitin Only
0.7 (0.3-1.4)
0.01
0.5 (0.2-1.3)
0.01
--Glucosamine and Chondroitin
6.2 (1.5-26.3)
0.02
7.4 (1.0-56.8)
0.07
-Sex
Women
1.0 (referent)
1.0 (referent)
1.0 (referent)
Men
0.9 (0.7-1.0)
0.02
1.0 (0.8-1.1)
0.70
0.9 (0.6-1.3)
0.48
Age
18-39 years old
1.0 (referent)
1.0 (referent)
1.0 (referent)
40-55 years old
1.1 (0.9-1.5)
0.79
1.1 (0.8-1.5)
0.72
1.8 (0.9-3.5)
0.30
56-70 years old
1.5 (1.1-1.9)
0.00
1.4 (1.0-1.9)
0.00
2.4 (1.2-4.5)
0.02
71-84 years old
1.0 (0.8-1.3)
0.10
0.9 (0.7-1.3)
0.06
1.3 (0.7-2.4)
0.36
>85 years old
1.0 (0.7-1.4)
0.21
1.0 (0.7-1.5)
0.58
1.4 (0.6-3.4)
0.77
Race/Ethnicity
White
1.0 (referent)
1.0 (referent)
1.0 (referent)
Black/African American
1.2 (1.0-1.4)
0.04
1.2 (0.9-1.4)
0.15
1.7 (1.1-2.8)
0.28
Hispanic/Latino
0.9 (0.7-1.1)
0.69
0.7 (0.6-0.9)
0.11
1.9 (1.2-2.8)
0.09
American Indian or Alaskan Native
0.7 (0.5-0.9)
0.03
0.7 (0.5-1.1)
0.18
0.9 (0.2-3.9)
0.53
Asian
1.0 (0.5-2.2)
0.83
1.2 (0.4-3.7)
0.57
1.9 (0.4-10.6)
0.68
BMI Category
≤ 24.9
1.0 (referent)
1.0 (referent)
1.0 (referent)
>24.9 and <30.0
1.2 (1.0-1.5)
0.30
1.2 (1.0-1.5)
0.06
1.7 (1.1-2.7)
0.23
≥ 30.0
1.8 (1.5-2.1)
<0.01
2.0 (1.7-2.3)
<0.01
1.7 (1.1-2.8)
0.19
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Education
Did Not Complete High School
1.0 (referent)
1.0 (referent)
1.0 (referent)
GED
1.1 (0.7-1.6)
0.84
1.0 (0.6-1.5)
0.62
0.7 (0.2-2.4)
0.96
High School Diploma
1.1 (0.9-1.3)
0.89
1.1 (0.9-1.4)
0.80
0.8 (0.4-1.5)
0.89
Some College, No Degree
1.1 (0.9-1.4)
0.60
1.1 (0.9-1.5)
0.39
0.6 (0.3-1.2)
0.35
Associate’s Degree
1.2 (0.9-1.6)
0.17
1.3 (1.0-1.8)
0.05
0.7 (0.3-1.5)
0.74
Bachelor's Degree
1.0 (0.8-1.2)
0.43
0.9 (0.7-1.2)
0.15
1.1 (0.5-2.6)
0.14
Master's, Professional, or
0.9 (0.7-1.2)
0.11
1.0 (0.8-1.3)
0.73
0.5 (0.2-1.0)
0.06
Doctoral Degree
Poverty Level
Above Poverty Line
1.0 (referent)
1.0 (referent)
1.0 (referent)
Below Poverty Line
1.3 (1.1-1.6)
0.04
1.3 (1.1-1.6)
0.03
2.6 (1.5-4.7)
<0.01
Unknown
1.1 (0.9-1.4)
0.63
1.1 (0.8-1.3)
0.50
0.8 (0.4-1.5)
0.03
Region
Northeast
1.0 (referent)
1.0 (referent)
1.0 (referent)
Midwest
1.2 (0.9-1.4)
0.70
1.3 (1.0-1.7)
0.95
0.7 (0.4-1.2)
0.21
South
1.3 (1.0-1.6)
0.08
1.5 (1.2-1.9)
0.01
0.9 (0.5-1.5)
0.69
West
1.0 (1.0-1.6)
0.13
1.5 (1.1-1.9)
0.11
0.8 (0.5-1.4)
0.92
No Other Health Conditions
1.0 (referent)
1.0 (referent)
1.0 (referent)
Other Health Conditions
1.4 (1.2-1.6)
<0.01
1.6 (1.4-1.9)
<0.01
1.4 (0.9-2.2)
0.16
No Energy Therapies
1.0 (referent)
1.0 (referent)
1.0 (referent)
Energy Therapies
1.1 (0.8-1.4)
0.53
1.1 (0.8-1.5)
0.48
0.9 (0.4-2.3)
0.91
No Acupuncture
1.0 (referent)
1.0 (referent)
1.0 (referent)
Acupuncture
1.3 (0.8-2.0)
0.29
1.4 (0.9-2.4)
0.16
0.5 (0.2-1.9)
0.35
No Mind-Body Therapies
1.0 (referent)
1.0 (referent)
1.0 (referent)
Mind-Body Therapies
1.3 (1.0-1.8)
0.06
1.4 (1.1-2.0)
0.02
0.4 (0.2-0.9)
0.03
No Chiropractic/ Osteopathic Therapy
1.0 (referent)
1.0 (referent)
1.0 (referent)
Chiropractic/ Osteopathic Therapy
1.3 (1.0-1.6)
0.02
1.3 (1.0-1.6)
0.03
1.3 (0.6-2.9)
0.46
*Estimates presented were found using a logistic regression.
**Chondroitin only and glucosamine and chondroitin yielded a small sample size in rheumatoid arthritis therefore, could not be analyzed.

MULTIVARIABLE ANALYSES
Table 11 presents adjusted odds ratios, 95% Confidence intervals (95% CI), and p-values
for selected characteristics and self-reported 12 month improved health among persons with any
arthritis, unspecified arthritis, and rheumatoid arthritis. After adjusting for age, education, energy
therapies, and mind-body therapies, supplement use (glucosamine only, chondroitin only, and
both glucosamine and chondroitin) was not associated with self-reported improved health among
persons with any arthritis. After adjusting for sex, age, BMI, education, mind-body therapies,
and chiropractic/osteopathic therapy, supplement use (glucosamine only, chondroitin only, and
both glucosamine and chondroitin) was not associated with self-reported 12 month improved
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health among persons with unspecified arthritis. After adjusting for mind-body and
chiropractic/osteopathic therapies, supplement use (glucosamine only, chondroitin only, and both
glucosamine and chondroitin) was not associated with self-reported 12 month improved health
among persons with rheumatoid arthritis.
Adjusted age, education, energy therapies, and mind-body therapies were characteristics
that yielded statistically significant associations with self-reported past 12 month improved
health among persons with any arthritis. When compared to persons 18 to 39 years old, persons
71 to 84 years old were 0.4 times likely to report past 12 month improved health (adjusted OR=
0.4; p= 0.04) and persons 85 years or older were 0.3 times likely to report past 12 month
improved health (adjusted OR= 0.3; p= <0.01). When compared to persons that did not complete
high school, persons with an associate’s degree were 1.3 times likely to report past 12 month
improved health than persons that did not complete high school (adjusted OR= 1.3; p= 0.02).
Persons that engaged in energy therapies one or more times within the 12 months prior to the
administration of the survey were 1.5 times likely to report past 12 month improved health than
persons that did not (adjusted OR=1.5; p= <0.01). Persons that engaged in mind-body therapies
one or more times within the 12 months prior to the administration of the survey were also 1.5
times likely to report past 12 month improved health than persons that did not (adjusted
OR=1.5; p= <0.01).
Adjusted sex, age, BMI, education, mind-body therapies, and chiropractic/osteopathic
therapy were characteristics that yielded statistically significant associations with self-reported
12 month improved health among persons with unspecified arthritis, as illustrated in Table 11.
Men were 0.8 time likely to report past 12 month improved health than women (adjusted OR=
0.8; p= 0.03). When compared to persons 18 to 39 years old, person 71 to 84 years old were 0.4
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time likely to report past 12 month improved health (adjusted OR= 0.4; p= 0.03) and persons 85
years and older were 0.3 time likely to report past 12 month improve health (adjusted OR= 0.3;
p= <0.01). When compared to persons that did not complete high school, persons with a high
school diploma were 0.9 times likely to report past 12 month improved health (adjusted OR=
0.9; p= 0.02). Obese persons (BMI ≥ 30) were 1.3 times likely to report past 12 month improved
health than person who were either underweight or normal weight (adjusted OR= 1.3; p= 0.02).
Persons that engaged in energy therapies one or more times within the 12 months prior to the
administration of the survey were 1.5 times likely to report past 12 month improved health than
persons that did not (adjusted OR=1.5; p= 0.01). Persons that engaged in mind-body therapies
one or more times within the 12 months prior to the administration of the survey were also 1.6
times likely to report past 12 month improved health than persons that did not (adjusted
OR=1.6; p= 0.02).
Adjusted mind-body and chiropractic/osteopathic therapies yielded statistically
significant associations with self-reported 12 month improved health among persons with
rheumatoid arthritis, as illustrated in Table 11. When compared to persons that did not use mindbody therapies in the 12 months prior to administration of the survey, persons that did use mindbody therapies were about two times likely to report improved health (adjusted OR= 1.9; p=
0.05). Persons that saw a chiropractor or osteopathic practitioner one or more times within the 12
months prior to taking the survey were 1.8 time likely to report improved health than persons
that did not (adjusted OR= 1.8; p= 0.04).
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Table 11: Adjusted Odds Ratio for Glucosamine Use Within the Past 12 Months and Reports of Improved Health when Compared
to 12 Months Ago among Sample Adults Ages 18+ with Any Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis, 2012
National Health Interview Survey (NHIS)
Self-Reported Improved Health over a 12-Month Period
Characteristics
No Supplement Use
Glucosamine Only
Chondroitin Only
Glucosamine and Chondroitin
Sex
Women
Men
Age
18-39 years old
40-55 years old
56-70 years old
71-84 years old
>85 years old
Race/Ethnicity
White
Black/African American
Hispanic/Latino
American Indian or Alaskan Native
Asian
BMI Category
≤ 24.9
>24.9 and <30.0
≥ 30.0
Education
Did Not Complete High School
GED
High School Diploma
Some College, No Degree
Associate’s Degree
Bachelor's Degree
Master's, Professional, or Doctoral Degree
Poverty Level
Above Poverty Line
Below Poverty Line
Unknown
Region
Northeast
Midwest
South
West
No Other Health Conditions
Other Health Conditions

Any Arthritis
n= 7654
OR (95%CI)
p-value
1.0 (referent)
1.1 (0.8-1.6)
0.19
0.6 (0.2-1.3)
0.31
0.9 (0.6-1.3)
0.96

Unspecified Arthritis
n= 6016
OR (95%CI)
p-value
1.0 (referent)
1.0 (0.6-1.5)
0.51
0.6 (0.2-1.8)
0.45
0.9 (0.6-1.3)
0.98

1.0 (referent)
0.9 (0.7-1.0)

0.06

1.0 (referent)
0.8 (0.7-1.0)

0.03

---

---

1.0 (referent)
0.6 (0.4-0.7)
0.5 (0.4-0.7)
0.4 (0.3-0.6)
0.3 (0.2-0.4)

0.15
0.40
0.04
<0.01

1.0 (referent)
0.5 (0.4-0.7)
0.5 (0.4-0.7)
0.4 (0.3-0.6)
0.3 (0.1-0.4)

0.40
0.45
0.03
<0.01

------

------

------

------

------

------

------

------

----

---

1.0 (referent)
1.1 (0.9-1.4)
1.3 (1.0-1.6)

0.89
0.02

----

----

1.0 (referent)
0.8 (0.5-1.3)
0.9 (0.7-1.2)
1.2 (0.9-1.6)
1.3 (1.0-1.7)
1.1 (0.8-1.5)
1.2 (0.9-1.6)

0.14
0.06
0.14
0.02
0.55
0.21

1.0 (referent)
0.9 (0.5-1.6)
0.9 (0.6-1.2)
1.3 (0.9-1.8)
1.3 (1.0-1.9)
1.1 (0.8-1.6)
1.3 (0.9-1.7)

0.42
0.02
0.06
0.08
0.82
0.21

--------

--------

----

----

----

----

----

----

1.0 (referent)
1.0 (0.8-1.3)
1.0 (0.8-1.2)
1.1 (0.9-1.4)
---

0.88
0.32
0.13
---

-------

-------

-------

-------
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Rheumatoid Arthritis
n= 898
OR (95%CI)
p-value
1.0 (referent)
1.2 (0.6-2.5)
0.25
0.2 (0.0-2.2)
0.18
1.2 (0.4-3.2)
0.38

No Energy Therapies
1.0 (referent)
1.0 (referent)
1.0 (referent)
Energy Therapies
1.5 (1.1-1.9)
<0.01
1.5 (1.1-2.0)
0.01
1.8 (0.9-3.4)
No Acupuncture
1.0 (referent)
1.0 (referent)
1.0 (referent)
Acupuncture
1.4 (0.9-2.0)
0.13
1.4 (0.9-2.2)
0.14
2.3 (1.0-5.3)
No Mind-Body Therapies
1.0 (referent)
1.0 (referent)
1.0 (referent)
Mind-Body Therapies
1.5 (1.1-2.1)
<0.01
1.6 (1.1-2.3)
0.02
1.9 (1.0-3.8)
No Chiropractic/ Osteopathic Therapy
1.0 (referent)
1.0 (referent)
1.0 (referent)
Chiropractic/ Osteopathic Therapy
1.2 (0.9-2.0)
0.12
1.1 (0.9-1.5)
0.29
1.8 (1.0-3.1)
*Multivariable logistic regression models used to present the adjusted odds ratios, 95% Confidence Intervals (CI) and p-values.
**Variables denoted by ‘—‘ were not included in the arthritis specific model.

Table 12 presents adjusted odds ratios, 95% Confidence intervals (95% CI), and p-values
for selected characteristics and self-reported joint pain, aching, and stiffness within the past 30
days prior to taking the survey among persons with any arthritis, unspecified arthritis, and
rheumatoid arthritis. After adjusting for sex, age, race, BMI, poverty level, other health
conditions, and other CAM therapies (acupuncture, energy, mind-body, and chiropractic/
osteopathic therapies), the use of chondroitin only one or more times during the past 30 days
prior to taking the survey was found to be associated with self-reported past 30 day joint pain,
aching, and stiffness among persons with any arthritis (adjusted OR= 0.6; p= <0.01).
Glucosamine and chondroitin was also found to be associated with self-reported past 30 day joint
pain, aching, and stiffness among persons with any arthritis (adjusted OR= 5.7; p= 0.03).
Glucosamine only was not associated with past 30 day joint pain, aching, and stiffness among
persons with any arthritis (adjusted OR= 2.1; p= 0.26), as can be seen in Table 12. After
adjusting for age, BMI, poverty level, region, other health conditions, and other CAM therapies
(acupuncture, energy, mind-body, and chiropractic/osteopathic therapies), use of chondroitin
only was found to be associated with past 30 day joint pain, aching, and stiffness among persons
with unspecified arthritis (adjusted OR= 0.5; p= 0.02). Glucosamine only and glucosamine and
chondroitin were not associated with past 30 day joint pain, aching, and stiffness among persons
with unspecified arthritis (p> 0.05). After adjusting for poverty level and other CAM therapies
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0.07
0.06
0.05
0.04

(acupuncture, energy, mind-body, and chiropractic/osteopathic therapies), glucosamine only was
also not associated with past 30 day joint pain, aching, and stiffness among persons with
rheumatoid arthritis (p>0.05), as can be seen in Table 12.
Adjusted sex, BMI, poverty level, other health conditions, and chiropractic/ osteopathic
therapy were characteristics that yielded statistically significant associations with self-reported
past 30 day joint pain, aching, and stiffness among persons with any arthritis. Men were 0.8
times likely to report past 30 day joint pain, aching, and stiffness than women (adjusted OR= 0.8;
p= 0.02). Obese persons (BMI≥ 30) 1.6 times likely to report past 30 day joint pain, aching, and
stiffness than persons that were either underweight or normal weight (BMI< 25) (adjusted OR=
1.6; p= <0.01). When compared to person above the poverty line, person below the poverty line
were 1.4 time more likely to report past 30 day joint pain, aching, and stiffness (adjusted OR=
1.4; p= 0.03). Persons with other health conditions were 1.3 time likely to report past 30 day
joint pain, aching, and stiffness than persons without these conditions (adjusted OR= 1.3; p=
<0.01). Persons that saw a chiropractor or osteopathic practitioner one or more times within the
12 months prior to taking the survey were 1.2 times likely to report past 30 day joint pain,
aching, and stiffness than persons that did not (adjusted OR= 1.2; p= 0.05).
Adjusted age, BMI, poverty level, region, other health conditions, chiropractic/
osteopathic therapy, and mind-body therapy were characteristics that yielded statistically
significant associations with self-reported past 30 day joint pain, aching, and stiffness among
persons with unspecified arthritis. When compared to persons 18 to 39 years old, persons 56 to
70 years old were 1.3 times likely to report past 30 day joint pain, aching, and stiffness (adjusted
OR= 1.4; p= 0.01). Obese persons (BMI≥ 30) were 1.8 times likely to report past 30 day joint
pain, aching, and stiffness than persons that were either underweight or normal weight (BMI<
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25) (adjusted OR= 1.8; p= <0.01). Persons with unknown poverty level were 1.8 times likely to
report past 30 day joint pain, aching, and stiffness than persons below poverty level (adjusted
OR= 1.8; p= <0.01). Persons in the South were 1.6 times likely to report past 30 day joint pain,
aching, and stiffness than persons in the Northeast region of the U.S (adjusted OR= 1.6; p=
<0.01). Persons with other health conditions were 1.5 times likely to report past 30 day joint
pain, aching, and stiffness than persons without other health conditions (adjusted OR= 1.5; p=
<0.01). Persons that engaged in mind-body therapies one or more times within the 12 months
prior to the administration of the survey were also 1.4 times likely to report past 30 day joint
pain, aching, and stiffness than persons that did not (adjusted OR=1.4; p= 0.04). Persons that
saw a chiropractor or osteopathic practitioner one or more times within the 12 months prior to
taking the survey were 1.3 times likely to report past 30 day joint pain, aching, and stiffness than
persons that did not (adjusted OR= 1.3; p= 0.04).
Adjusted poverty level, chiropractic/osteopathic therapy, and mind-body therapy were
characteristics that yielded statistically significant associations with self-reported past 30 day
joint pain, aching, and stiffness among persons with rheumatoid arthritis. When compared to
persons above poverty level, persons below poverty level were 2.6 time likely to report past 30
day joint pain, aching, and stiffness (adjusted OR= 2.6; p= <0.01) and persons with unknown
poverty level were 0.8 times likely to report past 30 day joint pain, aching, and stiffness
(adjusted OR= 0.8; p= 0.05). Persons that saw a chiropractor or osteopathic practitioner one or
more times within the 12 months prior to taking the survey were two times likely to report past
30 day joint pain, aching, and stiffness than persons that did not (adjusted OR= 2.0; p= 0.01).
Persons that engaged in mind-body therapies one or more times within the 12 months prior to the
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administration of the survey were also 1.4 times likely to report past 30 day joint pain, aching,
and stiffness than persons that did not (adjusted OR=1.4; p= 0.02).

Table 12: Adjusted Odds Ratio for Glucosamine and/or Chondroitin Use within the Past 30 days and Reports of Joint Pain, Aching, or Stiffness
in or around a Joint over the Past 30 Days among Sample Adults Ages 18+ with Any Arthritis, Unspecified Arthritis, and Rheumatoid Arthritis,
2012 National Health Interview Survey (NHIS)
Self-Reported Joint Pain in Past 30 Days
Any Arthritis
Unspecified Arthritis
Rheumatoid Arthritis
Characteristics
n= 7654
n= 6016
n= 898
OR (95% CI)
p-value
OR (95% CI)
p-value
OR (95% CI)
p-value
No Supplement Use
1.0(referent)
1.0 (referent)
1.0 (referent)
Glucosamine Only
2.1 (1.5-3.0)
0.26
2.5 (1.7-3.6)
0.22
0.8 (0.3-2.0)
0.57
Chondroitin Only
0.6 (0.3-1.2)
<0.01
0.5 (0.2-1.1)
<0.01
--Glucosamine and Chondroitin
5.7 (1.3-24.3)
0.03
6.7 (0.2-1.1)
0.08
--Sex
Women
1.0 (referent)
----Men
0.8 (0.7-1.0)
0.02
----Age
18-39 years old
1.0 (referent)
1.0 (referent)
--40-55 years old
1.1 (0.8-1.4)
0.69
1.1 (0.8-1.5)
0.94
--56-70 years old
1.4 (1.1-1.8)
<0.01
1.3 (1.0-1.8)
0.01
--71-84 years old
1.0 (0.7-1.3)
0.10
1.0 (0.7-1.4)
0.09
-->85 years old
1.0 (0.7-1.5)
0.72
1.2 (0.8-1.8)
0.60
--Race/Ethnicity
White
1.0 (referent)
----Black/African American
1.1 (0.9-1.3)
0.13
----Hispanic/Latino
0.8 (0.7-1.0)
0.53
----American Indian or Alaskan Native
0.7 (0.5-1.0)
0.20
----Asian
0.9 (0.4-2.0)
0.98
----BMI Category
≤ 24.9
1.0 (referent)
1.0 (referent)
-->24.9 and <30.0
1.2 (1.0-1.5)
0.57
1.2 (1.0-1.4)
0.09
--≥ 30.0
1.6 (1.4-2.0)
<0.01
1.8 (1.5-2.2)
<0.01
--Education
Did Not Complete High School
------GED
------High School Diploma
------Some College, No Degree
------Associate’s Degree
------Bachelor's Degree
------Master's, Professional, or
------Doctoral Degree
Poverty Level
Above Poverty Line
1.0 (referent)
1.0 (referent)
1.0 (referent)
Below Poverty Line
1.4 (1.1-1.7)
0.03
1.2 (1.0-1.4)
0.09
2.6 (1.5-4.7)
<0.01
Unknown
1.1 (0.9-1.4)
0.64
1.8 (1.5-2.2)
<0.01
0.8 (0.4-1.6)
0.05
Region
Northeast
--1.0 (referent)
--Midwest
--1.3 (1.0-1.7)
0.88
--South
--1.6 (1.2-2.0)
<0.01
--West
--1.5 (1.1-1.9)
0.13
---
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No Other Health Conditions
1.0 (referent)
1.0 (referent)
--Other Health Conditions
1.3 (1.1-1.5)
<0.01
1.5 (1.3-1.8)
<0.01
--No Energy Therapies
1.0 (referent)
1.0 (referent)
1.0 (referent)
Energy Therapies
1.0 (0.8-1.4)
0.78
1.1 (0.8-1.5)
0.58
1.3 (0.6-2.6)
0.47
No Acupuncture
1.0 (referent)
1.0 (referent)
1.0 (referent)
Acupuncture
1.2 (1.0-1.8)
0.51
1.3 (0.8-2.2)
0.27
0.5 (0.2-1.2)
0.12
No Mind-Body Therapies
1.0 (referent)
1.0 (referent)
1.0 (referent)
Mind-Body Therapies
1.2 (0.9-1.6)
0.18
1.4 (1.0-2.0)
0.04
0.4 (0.2-0.8)
0.02
No Chiropractic/ Osteopathic Therapy
1.0 (referent)
1.0 (referent)
1.0 (referent)
Chiropractic/ Osteopathic Therapy
1.2 (0.7-1.8)
0.05
1.3 (1.0-1.6)
0.04
2.0 (1.2-3.4)
0.01
*Multivariable logistic regression models used to present adjusted odds ratios, 95% Confidence Intervals (CI) and p-values.
**Chondroitin only and glucosamine and chondroitin yielded a small sample size in rheumatoid arthritis therefore, could not be analyzed. This is
Denoted by ‘—‘.
***Other variable denoted by ‘--‘ were not included in the arthritis specific model.
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CHAPTER V
DISCUSSION & CONCLUSION
DISCUSSION
This study set out to identify the socio-demographic characteristics of U.S. adults with
any arthritis, unspecified arthritis, and rheumatoid arthritis, identify their use of glucosamine
and/or chondroitin, and to determine if reports of improved health or reports of joint pain,
aching, and stiffness differs based on glucosamine and/or chondroitin use. In 2012,
approximately 21.8% of U.S adults had any arthritis, 17.0% had unspecified arthritis, and 2.5%
had rheumatoid arthritis. This thesis found that women were more likely than men to report some
form of arthritis. This was expected because gender, particularly being a woman, has been
identified as a risk factor for arthritis (Johnson & Hunter 2014; Turkiewicz et al. 2014). The
prevalence of any arthritis, unspecified arthritis, and rheumatoid arthritis increases with age and
BMI. Both of these characteristics were previously identified as risk factors for arthritis (Johnson
& Hunter 2014). In addition, persons with diabetes and/or heart conditions (other health
conditions) had prevalence rates of some form of arthritis more than twice of that of persons who
did not have other health conditions. A previous study similarly found large proportions of
persons with arthritis to have comorbidities such as diabetes and heart disease (Barbour et al.
2013).
When assessing past 12 month supplement use among persons with any arthritis,
approximately 3.7% used glucosamine, 0.4% used chondroitin, and 3.4% used both glucosamine
and chondroitin. When assessing past 30 day supplement use among persons with any arthritis,
approximately 5.1% of persons with any arthritis used glucosamine, 0.6% used chondroitin, and
0.4% used both glucosamine and chondroitin. Approximately 3.7% of persons with unspecified
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arthritis reported past 12 month glucosamine use, 0.5% reported past 12 month chondroitin use,
and 3.8% reported past 12 month both glucosamine and chondroitin use. Approximately 5.5% of
persons with unspecified arthritis had past 30 day use of glucosamine, 0.5% had past 30 day use
of chondroitin, and 0.4% had past 30 day use of both glucosamine and chondroitin.
Approximately 2.4% of persons with rheumatoid arthritis used glucosamine while 0.3% used
chondroitin, and 2.1% used both glucosamine and chondroitin within the past 12 months.
Approximately 2.9% of persons with rheumatoid arthritis had past 30 day use of glucosamine
while 0.7% used chondroitin, and 0.5% used both glucosamine and chondroitin.
Women used more of all supplements (past 12 months and past 30 days) except past 12
month use of chondroitin among persons with any arthritis. Among persons with unspecified
arthritis, women were more likely than men to report past 12 month glucosamine and past 12
month both glucosamine and chondroitin use. Men, however, were more likely to be chondroitin
users (57.3%). Among persons with rheumatoid arthritis, the majority of glucosamine and both
glucosamine and chondroitin users were women (59.3% and 58.0% respectively) however; men
made up 94.0% of chondroitin use.
Persons 56 to 70 years old had the highest proportion of past 12 month and 30 day
supplement use among persons with unspecified arthritis. Among persons with unspecified
arthritis, persons 40-55 years old made up 85.1% of 12 month chondroitin use. Persons age 56 to
70 years old with unspecified arthritis reported the highest proportion of past 30 day supplement
use (57.9% glucosamine, 57.1% chondroitin, 33.0% both glucosamine and chondroitin). Persons
56 to 70 years old reported the largest proportion of past 30 day glucosamine use (42.9%) and
chondroitin use (85.8%) among persons with rheumatoid arthritis. A previous study identified
persons 50 to 59 years of age as having the highest prevalence of CAM use (Barnes et al. 2008).
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While part of the 50 to 59 and the 56 to 70 age groups overlap, it was unexpected to find that
persons 18 to 39 years old reported the largest proportion of past 30 day use of both glucosamine
and chondroitin among persons with rheumatoid arthritis.
White people accounted for the majority of all past 30 day supplement use among
persons with any arthritis. Past 30 day supplement use was most common among white persons
with unspecified arthritis (90.9% glucosamine, 78.3% chondroitin, and 67.2% both glucosamine
and chondroitin). Persons in the Northeast had the lowest prevalence of any past 12 month and
past 30 day supplement use among persons with any arthritis. Persons in the West accounted for
a large proportion of past 12 month glucosamine use while a large proportion of chondroitin use
was in the Midwest among persons with any arthritis. The Northeast also had the lowest
proportion of any past 30 day supplement use among persons with unspecified arthritis. Among
persons with unspecified arthritis, more than half (54.9%) of past 12 month chondroitin use were
from persons in the Midwest. Similarly, a large proportion of persons with rheumatoid arthritis
that reported past 30 day chondroitin use were from the Midwest (60.9%). These findings are
somewhat similar to the results of a Canadian study. This study found that glucosamine use
occurred more in the western regions when compared to all other regions (Hopman et al. 2006).
Obese (BMI ≥ 30.0) individuals had the highest proportion of past 12 month glucosamine
and chondroitin use (42.9% and 94.0% respectively) among persons with unspecified arthritis.
Similarly, obese (BMI ≥ 30.0) individuals had the highest proportion of past 12 month
glucosamine and chondroitin use (42.9% and 94.0% respectively) among persons with
rheumatoid arthritis. These findings were surprising to find. In a study observing CAM use
among overweight and obese persons with radiographic knee osteoarthritis, BMI was inversely
associated with CAM use. Persons classified as obese (BMI ≥ 30) were less likely to use CAM
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therapies, alone or in combination with conventional medications when compared to persons
underweight or normal weight (BMI < 25) (Lapane et al. 2013).
Persons above the poverty line had the highest proportion of supplement use among
persons with any arthritis. Persons above poverty level also had the highest proportion of all past
30 day supplement use (93.0% glucosamine, 76.6% chondroitin, and 95.5% both glucosamine
and chondroitin) among persons with unspecified arthritis. Past 12 month glucosamine use and
past 12 month both glucosamine and chondroitin use were most common among persons above
poverty level (83.3% and 100.0% respectively) with rheumatoid arthritis. These findings
coincides with the Australian study of persons 45 years of age and older that found that higher
income is associated with glucosamine use (Sibbritt et al. 2012). However, persons below
poverty level made up the highest proportion of past 12 month chondroitin use (85.1%) among
persons with rheumatoid arthritis.
MAJOR FINDINGS
Past 12 month use of glucosamine only was not associated with reported past 12 month
improved health among persons with any arthritis (adjusted OR=1.1; p= 0.19), unspecified
arthritis (adjusted OR= 1.0; p= 0.51), or rheumatoid arthritis (adjusted OR=1.2; p= 0.25). Past 30
day use of glucosamine only was also not associated with reports of past 30 day joint pain,
aching, and stiffness among persons with any arthritis (adjusted OR= 2.1; p= 0.26), unspecified
arthritis (adjusted OR= 2.5; p= 0.22), or rheumatoid arthritis (adjusted OR= 0.8; p= 0.57). Past
12 month use of chondroitin only was not associated with reports of past 12 month improved
health among persons with any arthritis (adjusted OR= 0.6; p= 0.31), unspecified arthritis
(adjusted OR= 0.6; p= 0.45), or rheumatoid arthritis (adjusted OR= 0.2; p= 0.18). Past 30 day
use of chondroitin only was associated with reported past 30 day joint pain, aching, and stiffness
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among persons with any arthritis (adjusted OR= 0.6; p= <0.01) and unspecified arthritis
(adjusted OR= 0.5; p= <0.01). Past 12 month use of both glucosamine and chondroitin was not
associated with reports of past 12 month improved health among persons with any arthritis
(adjusted OR= 0.9; p= 0.96), unspecified arthritis (adjusted OR= 0.9; p= 0.98), or rheumatoid
arthritis (adjusted OR= 1.2; p= 0.38). Past 30 day use of both glucosamine and chondroitin was
associated with reports of past 30 day joint pain, aching, and stiffness among persons with any
arthritis (adjusted OR= 5.7; p= 0.03) but was not associated with joint pain, aching, and stiffness
among persons with unspecified arthritis (adjusted OR= 6.7; p= 0.08).
There were no observable associations between past 12 month use of glucosamine and/or
chondroitin and reports of improved health among persons with any arthritis, unspecified
arthritis, or rheumatoid arthritis. These findings support the claims from clinical studies
presented by Kwoh and Clegg (Kwoh et al. 2014; Clegg et al. 2006). This thesis finds no
evidence to support the marketed claim that glucosamine and/or chondroitin can improve the
health conditions of persons with arthritis.
The association of past 30 day use of chondroitin only and reports of past 30 day joint
pain, aching, and stiffness among persons with any arthritis and unspecified arthritis yielded a
decreased odds. This suggests that persons with past 30 day use of chondroitin were less likely to
report joint pain, aching, and stiffness than persons that did not use the observed supplements.
Several factors could have contributed to these findings. To start, only a small proportion of the
observed subpopulations were users of chondroitin only. In addition, when compared to
glucosamine and combination (glucosamine and chondroitin) supplements, chondroitin seems to
be less readily available on the market. Finally, this finding may also suggest that the use of
chondroitin alone can be for reasons other than those associated with arthritis.
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Past 30 day use of both glucosamine and chondroitin was also found to be associated
with self-reported past 30 day joint pain, aching, and stiffness among persons with any arthritis.
This finding would suggest that persons who use glucosamine and chondroitin within the 30 days
prior to administration of the survey were more likely to report past 30 day joint pain, aching,
and stiffness. This could also be interpreted to mean that persons that experience joint pain are
more likely to use chondroitin and glucosamine. This may mean that marketing glucosamine and
chondroitin together as a CAM treatment for persons with arthritis has been effective.
Glucosamine and/or chondroitin are marketed to persons with arthritis for their potential
chondroprotective properties (Gibson et al. 2014). These findings may be used to provide insight
on the effectiveness of marketing. It is important to note that glucosamine and/or chondroitin are
classified as dietary supplements therefore, are not regulated drugs. Marketing claims may not be
backed by scientific findings.
IMPORTANCE
While there are several clinical studies examining the effects of glucosamine and/or
chondroitin on arthritic and rheumatoid condition and outcomes, there are very few observational
studies that do the same. To date, there are no observational studies that have specifically
investigated the relationship between self-reported glucosamine and/or chondroitin use among
persons with some form of arthritis and reports of improved health or self-reported pain. While
this study was limited to the data provided in the 2012 NHIS adult sample, it fills in the literature
gap by providing observational analyses of these associations among persons with any arthritis,
unspecified arthritis, and rheumatoid arthritis with reports of improved health and joint pain,
aching, or stiffness.
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LIMITATIONS
Although 2012 NHIS data included variables specifically for some arthritis and
rheumatoid conditions (i.e. rheumatoid arthritis, gout, lupus, and fibromyalgia), there was not a
variable specifically for osteoarthritis. Previous clinical studies examined the effect of
glucosamine use on osteoarthritis specifically (Bruyere & Reginster 2007; McAlindon et al.
2000; Jawahar et al. 2012); however, this cross-sectional observational study could not
investigate this relationship with the given data. Perhaps if future observational studies examine
this specific relationship, results would be different.
In addition, the exposure and outcome measurements for this study left room for
uncertainty. The question “Compared with 12 months ago, would you say your health is better, worse,
or about the same?” covers a large time frame. Various factors can affect a response to this

question and though the study was focused on persons with arthritis, a response to this question
could be unrelated. Likewise, the question “Please tell me which of these supplements you have
taken during the past 12 months?” covers a large time frame. Taking a supplement one or more
time may not be a good estimate to analyze.
The following questions are better measures in term of time frame: “Which of these
supplements have you taken during the past 30 days?” and “During the past 30 days, have you had
any symptoms of pain, aching, or stiffness in or around a joint?” However, they fall short of determining
an association with symptom improvement. Asking about joint pain is not the same as asking if joint pain
has decreased or been eliminated. Better measures to analyze this were not included in 2012 NHIS.
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FUTURE STUDIES
As previously mentioned, an analysis of the association of glucosamine and/or
chondroitin use among persons specifically with osteoarthritis and improved health could not be
analyzed. Future observational studies should examine this relationship as well as glucosamine
and/or chondroitin’s relationship with decreased joint pain among persons with specific forms of
arthritis. Perhaps, NHIS could include an “osteoarthritis” variable in future surveys. Finally,
while the findings of this study did not yield any statistically significant association between
glucosamine and/or chondroitin use and reports of improved health, future studies are needed
that can examine these relationships longitudinally through experimental study designs.
CONCLUSION
Past 12 month use of glucosamine and/or chondroitin is not associated with self-reported
12 month improved health among persons with any arthritis, unspecified arthritis, or rheumatoid
arthritis. Past 30 day glucosamine use was not associated with reports of past 30 day pain,
aching, and stiffness among person with any arthritis, unspecified arthritis, and rheumatoid
arthritis however, past 30 day use of chondroitin only and past 30 day use of both glucosamine
and chondroitin is associated with reports of past 30 day pain, aching, and stiffness among
person with any arthritis. Past 30 day use of chondroitin only is also associated with past 30 day
pain, aching, and stiffness among person with unspecified arthritis. Because marketing is
expected to have an effect on the factors found to be associated, this study warrants the need for
future studies on the effects of advertisement and supplement use.
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